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Non-enzymat 'ic glycation and oxidation play an important role in the 
pathogenesis of several diseases like diabetes and rheumatoid arthritis (Newkirk el al.. 
2003; Jakus, 2003; Schmitt et al., 2005). They also induce the accelerated 
accumulation of AGE products in tissues of diabetic patient, particularly with 
secondary complications like retinopathy, nephropathy and artherosclerosis (Cohen el 
ai, 2005; Defraigne, 2005). In diabetes mellitus and rheumatoid arthritis protein 
glycation and the formation of AGEs are accompanied by increased free radical 
activity that contributes toward the biomolecular damage (Ahmed, 2005; Drinda el al., 
2005; Sunahori cl al., 2006). AGE formation is an inevitable process in vivo and can 
be accelerated under pathological conditions such as oxidative stress. Oxidative stress 
and oxidative damage to tissues are common end points of chronic diseases such as 
diabetes and rheumatoid arthritis (Baynes and Thorpe, 1999; Ahmed el al., 2005). 
In the present study, human serum albumin (HSA) was glycated non-
enzymatically by incubating with glucose for 10 weeks. Glycated HSA was further 
modified by ROS generated by the irradiation of hydrogen peroxide with UV light al 
254 nm. Under these experimental conditions, the major species would be hydroxy! 
radical (OH), the most reactive of ROS. The modified HSA samples showed 
remarkable biophysical changes analyzed by gel electrophoresis, spectral analysis. 
circular dichroism spectropolarimctry and thermal denaturation studies. Estimation of 
ketoamine. carbony! and free amino groups revealed that glycation and oxidation 
attributed to the conformational and structural changes in HSA. 
The electrophoretic pattern of both modified HSA showed formation of high and 
low molecular weight aggregates. However. ROS-glycated HSA showed almost 
similar changes but with considerable decrease in their intensity which can be 
attributed to fragmentation of glycated HSA on ROS modification. UV spectra of 
glycated HSA showed hypochromicity, whereas, ROS-glycated HSA exhibited 
hyperchromicily as compared to unmodified HSA. These changes arc indicative of 
conformational changes in HSA on modificafions. Gl>cation causes shielding of 
aromatic amino acids contributing to hypochromicity. However, fragmentation by 
OH causes exposure of aromatic amino acids in glycated HSA towards solvent 
system resulting in hyperchromicity. The fluorescence spectra! studies of USA also 
showed the same pattern as observed in UV spectra as the same aromatic amino acids 
are involved in both spectral analyses. 
Tryptophan specific fluorescence was also carried out. Glycated HSA showed 
lower fluorescence intensity and quantum yield, as compared to ROS glycated USA 
showing higher tryptophan specific Huorcscence and quantum yield. The significant 
observation in this result was the blue shift on modifications. The blue shift was more 
in case of glycated I ISA than ROS-glycated HSA. The results reiterate the earlier 
observation of conformational changes in glycated USA whereas fragmentation 
appears to be one of prominent phenomena on ROS exposure. 
The melting temperature profile of glycated and ROS-glycated HSA showed a 
net increase of IS.TC and 8.8°C, respectively, as compared to unmodified protein. 
Once again it can be attributed to conformational stability of both modified HSA over 
their native form. However, ROS may causes disruption of weak bonds or 
fragmentation of glycated HSA and might be one of the reasons for increase in Tm 
value. 
Furthermore, colorimetric estimations were carried out to support the biophysical 
analysis. Ketoamine level was found to be significantly higher in case of both 
modified samples (with slight difference) as compared to native HSA, which showed 
negligible ketoamine content. Levels of carbonyl groups were also elevated in both 
cases, an important marker of both glycation and oxidative stress. However, the 
increase was more in ROS modified glycated HSA. Number of free amino groups in 
modified HSA samples was found to be half as compared to native HSA. ROS 
modification of glycated HSA resulted in appreciable increase in amino groups 
reiterating once again the fragmentation and structural changes in "OH-modified 
glycated polymer. 
Studies with various antioxidants, scavengers and metal chelators showed 
inhibition of different parameters in both the modified samples. Moreover, maximum 
inhibition with aminoguanidine and combination of two enzymatic antioxidant 
ii =:-'tl\ Sl.> 
(catalase and SOD) was observed showing a definite role of ROS in the modification 
of glycated HSA and AGE formation. 
Native and modified HSA samples were used to induce antibodies in rabbits and 
were found to be immunogenic, producing high titer antibodies. The antigenic 
specificity of the induced antibodies was studied by direct binding ELISA, 
immunodiffusion and competition ELISA. The immunogen showed a high degree of 
specificity for the induced antibodies, reiterated by gel retardation assay. Anti-
glycated and ROS-giycated HSA antibodies showed preferential recognition of 
glycated and ROS-glycated HSA in a competition assay. The induced antibodies were 
polyspecific in nature. 
Sera of diabetic patients were tested for the presence of antibodies reactive with 
native and both the modified samples of HSA. Direct binding ELISA showed greater 
recognition for modified HSA samples as compared to the native form ascertained by 
competition ELISA. Moreover, significantly higher recognition of modified HSA was 
observed in the sera of diabetic patients having secondary complications like 
retinopathy, nephropathy and artherosclerosis. The higher binding to both modified 
HSA over native HSA of antibodies in the sera of diabetic patients suggests the 
involvement of modified HSA in the production of autoantibodies in these patients. 
The binding specificity of glycated and ROS-glycated HSA with diabetic patient's IgG 
was reiterated by gel retardation assay. 
Glycation and ROS damage to human blood proteins was detected 
immunochemically using anti-glycated and anti-ROS-glycated HSA antibodies as 
probes. Albumin and IgG from different diabetic patients inhibited antibodies binding 
to their respective immunogen demonstrating the presence of glycated and ROS-
glycated epitopes on albumin and IgG molecules. Data obtained from our studies 
correlates to the earlier studies that glycation and glycoxidation causes in vivo protein 
modifications. 
The binding of circulating autoantibodies in rheumatoid arthritis with native, 
glycated and ROS-glycated HSA was also analyzed. Direct binding ELISA results 
showed preferential binding of rheumatoid arthritic autoantibodies to both modified 
111 
HSA in comparison to native HSA. Iniiibition ELISA reiterated the direct binding 
results. Gel retardation assay furtiier substantiated the binding of both modified HSA 
with rheumatoid arthritic autoantibodies. 
In conclusion, glycation and oxidation causes damage to HSA and render it 
highly immunogenic. Polyclonal antibodies generated against modified antigens 
showed preferential recognition of the immunogens. The induced antibodies as 
immunochemical probes detected glycation and oxidative damage to the blood 
proteins. Recognition of modified HSA samples by antibodies in sera of patients with 
diabetes and rheumatoid arthritis suggests glycation and oxidation induced blood 
proteins damage in these patients. It is, therefore, postulated that glycation and ROS 
modification of blood proteins appears to play a major role in the production of 
autoantibodies in disease state(s). 
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As the name indicates proteins are of paramount importance for biological 
systems. Out of total dry body weight, 3/4"' is made up of proteins. Proteins are 
like building blocks i.e. all the major structure and functional aspects of the body 
are carried out by protein molecules. All proteins are polymers of amino acids. 
Commonly occurring amino acids are 20 in number. 
It is almost impossible to correctly classify all proteins. However, proteins 
may be divided into three major groups; simple, conjugated and derived. Simple 
protein includes albumin, globulin, protamines, lectins and scleroproteins. 
Conjugated protein contains glycoproteins, lipoproteins, chromoproteins, 
phosphoproteins and metalloproteins. Derived proteins are degraded products of 
the native proteins (Vasudevan and Sreekumari, 2000). 
Human serum albumin 
Serum albumin belongs to a multigene family of proteins that includes a-
fetoprotein (AFP) and human group-specific component (GC). It is relatively 
large multi-domain protein, which, as the major soluble protein constituents of 
the circulatory system, has many physiological functions and has a half life of 
about 20 days (Ancell, 1939). 
Originally, the protein was referred to as "albumen" derived from latin 
word albus meaning "white", after the white colour of flocculant precipitate 
produced by various proteins. About 40% of the total albumin is found in the 
circulatory plasma (Peters, 1970) where as of ihc remaining 60%, about half 
resides in viscera and half in muscle and skin (Rabilloud el ciL, 1988). Albumin 
also occurs in milk (Phillippy and McCarty, 1979), amniotic fluid (Bala el ai, 
1987), semen (Blumsohn et al., 1991) and mammary cyst (Balbin el al., 1991). 
Albumin concentration in plasma declines slightly with age (Cooper and 
Gardner, 1989) but it is lower in new bonis (Cartlidge and Ruter, 1986) and as 
low as 20.0 g/1 in premature infants (Reading et al., 1990). Albumin is produced 
by the liver at the rate of 0.7 mg/g liver per hr (Peters, 1985). About 4-5% of 
albumin is daily replaced by hepatic synthesis (Olufemi et al., 1990). Albumin 
concentration in plasma is maintained through transcriptional control of the 
albumin gene by the anabolic hormones-insulin and somatotrophin (Hudson el 
ciL, 1987). Albumin synthesis is also highly dependent upon the supply of dietary 
amino acids (Kaysen et al., 1989). 
The first crystal structure of HSA at low resolution was reported by Carter 
and coworkers in 1989 (Carter et al., 1989; Carter and He, 1990). and its refined 
structure at 2.8 A resolution was published by the same group. The crystal 
structure of HSA shows that it is a three-domain, each domain contain two sub 
domains, heart shaped molecule that is predominantly composed of helical 
structure, with the remaining polypeptides in turns and extended or flexible 
regions that connect subdomains. Each domain is composed of two sub-domains 
that are stabilized by internal disulphide bridges (He and Carter, 1992). Albumin 
have 585 amino acids, this globular Mr 65 kDa protein contains 18 tyrosines, six 
methionines, one tryptophan, 17 disulphide bridges, and only one free cysteine, 
Cys34 (Sugio et al., 1999). Roughly 67% of HSA is helical, with the remainder 
in turns and extended polypeptide. The disulphide pairings in the primary 
structure of HSA predicted by Brown (Brown et al, 1989) (Fig. 1). 
Functions of human serum albumin 
Albumin contributes to about 80% of colloid blood pressure (Lundsgaard, 
1986) and 100% of protein effect in the acid base balance of plasma (Figge et al., 
1991). It acts as a carrier for long chain fatty acid (Brodersen et al., 1991; Cistola 
and Small, 1991), their acyl-coenzyme esters (Richards et al, 1990) and 
monoacyl phospholipids (Robinson et al., 1989) and affects the acfivity of lipase, 
esterases (Posner et al., 1987) and carnifine acyl transferase (Richards, 1991). 
Albumin binds to polyunsaturated fatty acids (Anel et al., 1989) and influences 
the stability (Haeggstrom et al., 1983), biosynthesis (Heinsolin et al., 1987) and 
transformations of prostaglandins (Dieter et al., 1990). It binds weakly to 
cholesterol (Deliconstantinos et al., 1986), bile acids (Malavolti et al., 1989), 
corticoid hormones (Watanabe el al., 1991; Mendel et al., 1990) sex hormone 
(Padridge, 1988), thyroxine (Petitpas et al., 2003) and is involved in transport of 
thyroid hormones (Mendel et al., 1990). Albumin also helps in the transport of 
Fig. 1. Schematic drawing of the HSA molecule. Each subdomain is marked with a 
different color (yellow for subdomain la; green, lb; red, Ila; magenta, lib; blue, 
Ilia; and cyan, Illb). N- and C-termini are marked as N and C, respectively. 
Arginine 117, lysine 351 and lysine 475, which may be binding sites for long-
chain fatty acids, are colored white (Sugio et al., 1999). 
pyridoxal phosphate (Fonda el ciL, 1991), cystein and glutathione (Joshi el uL, 
1987) by forming a covalent bond with these ligands. 
Albumin is also responsible for the transport and store housing of many 
therapeutic drugs in the blood stream (Bhattacharya et al., 2000). It is an 
important constituent of tissue culture media (Barnes and Sato. 1980) and serves 
as a medium to support the growth of bacteria, fungi and yeast (Callister et al.. 
1990; Morrill e/a/., 1990). 
Albumin is also proposed to serve high affinity to metals such as Cu^^  and 
Zn^^ and act as an eintioxidant function in the vascular compartment because of its 
scavenging of reactive oxygen and nitrogen species that are generated by basal 
aerobic metabolism and can be produced at increased rates during inflammation 
(Halliwell, 1988; Halliwell and Gutteridge, 1990). 
The anticoagulant and antithrombotic effects of albumin are poorly 
understood, this may be due to binding nitric oxide radicals inhibiting 
inactivation and permitting a more prolonged anti-aggregatory effect. 
It is possible that albumin has a role in limiting the leakage from capillary 
beds during stress that increases capillary permeability. This can be related to the 
ability of endothelial cells to control the permeability of their walls, and the 
spaces between them (Jakus and Rietbrock, 2004). 
Antigenecity of human serum albumin 
Albumin is highly antigenic giving high antibody titers in experimental 
animals due to which it was considered a popular source of antigen by 
immunologists' way before the development of precipitation reaction 
demonstrating molar ratio of bovine serum albumin (BSA) to antibody at 
equivalence point of 4:1 (Heidelberger, 1938). Recent studies, suggests that there 
are 13 major antigenic sites on HSA which are recognized by 19 monoclonal 
antibodies (Doyen et al., 1985) which is consistent with the maximum number of 
sites predicted by precipitation analysis thus indicating a third of the surface of 
albumin being antigenic. The synthetic antigenic sites localized with rabbit 
antisera against bovine serum albumin, were shown to bind considerable amounts 
of specific mouse 125 I-labcUed antibodies against bovine serum albumin, this 
showed that recognition of the antigenic sites of serum albumin is independent of 
the immunized species and is inherent in their structural and conformational 
uniqueness (Sakate and Atassi, 1980). Albumin-specific antibodies could also be 
used for albumin quantifications not only in urine, but also in other biological 
fluids. Anti-albumin monoclonoal antibodies could be used for the preparation of 
immunosorbents to deplete albumin from serum, which is a necessary stage of 
proteomic studies of blood proteins. A-HAlb/98 hybridoma secreting monoclonal 
antibody that specifically recognizes HSA, the ability of these antibodies is to 
quantitate urinary albumin in nanogram ranges (Aybay et ai, 1999: Aybay and 
Karakus, 2003). 
IgG reactivity towards glycated HSA was significantly higher in diabetic 
than in control sera (Vay et ai, 2000). Certain sera, IgG, IgM, IgA and IgE 
antibodies against formaldehyde-HSA could be measured. In the highest titered 
sera, it was shown that the IgG antibody was not directed against formaldehyde 
(F) alone or F-lysine but against an antigenic grouping of F-HSA. Some sera 
from dialysis patients had antibody activity against HSA. Two individuals with a 
history of F-induced asthma had no IgG antibodies but did have IgE antibodies 
against F-HSA and HSA (Fiehn el al., 2004). 
HSA specific polyclonal rabbit immunoglobulin was labelled with biotin 
and then used as the tracer antibody makes it a favourable candidate for 
utilization in diagnostic applications as well as in research studies (Aybay and 
Karalcus, 2003). 
Non-enzymatic glycation of proteins 
Non-enzymatic glycation is a process by which sugar is chemically bound 
to free s-amino groups of proteins but without the help of enzymes. However, in 
the recent years extensive investigations have been made on the glycation of 
proteins exposed directly to high glucose concentrations, e.g. lens ciystalline 
proteins (Stevvens et al., 1978), insulin (Dolhofer and Wieland, 1979), proteins 
of erythrocyte membrane (Miller el al., 1980), bovine serum albumin (Arakawa 
and Timasheff, 1982), human scrum albumin (Shaklai et al., 1984). enzymes 
(Coradello et ai, 1984), high and low-density lipoproteins (Krittein et al, 1990), 
peripheral nerve mylin (Green. 1980), elastin (Baydanoff el al, 1994) and 
immunoglobulin G (Newkirk el al., 2003). 
It is a classical covalent reaction in which, by means of N-glycoside 
bonding, the sugar-protein complex is formed through a series of chemical 
reactions described by a chemist Maillard (Singh et a/., 2001). Maillard reactions 
are complex and multilayer, and can be analyzed in three steps, (i) The sugar-
protein complex is formed (Irsl (Amadori rearrangement), an early product of 
non-enzymatic glycation lead to an intermediary products which is a precursor of 
all later compounds, (ii) It includes the formation of numerous intermediary 
products, some of which are very reactive and continue with glycation reaction. 
(iii) Final phase consists of polymerization reaction of the complex products 
formed in the second step, whereby heterogeneous structures named advanced 
glycation end products (AGE) are formed (Fig. 2). It was believed that the 
primary role in Maillard reactions was exclusively played by high glucose 
concentration. However, recent data show that, in spite of the fact that sugars are 
the main precursors of AGE compounds, numerous intermediary metabolites, i.e. 
a-oxoaldehydes, also creatively participate in non-enzymatic glycation reactions. 
Such intermediary products are generated during glycolysis (methylglyoxal) or 
along the poiyolic pathway, and can also be formed by autoxidation of 
carbohydrates (glyoxal). 
Advanced glycation end products 
Protein modification with AGE is irreversible, as there are no enzymes in 
the body that would be able to hydrolyze AGE compounds. These structures then 
accumulate during the lifespan of the protein on which they have been formed. 
Examples include all types of collagen, albumin, basic myelin protein, eye lens 
proteins, lipoproteins, and nucleic acid. It is now well documented that AGE 
change the function of many proteins, thus contributing to various late 
complications of diabetes mellitus (Turk, 1997). The major biological effects of 
excessive glycation include: inhibition of regulatory molecule binding, 
crosslinking of glycated proteins, trapping of soluble proteins by glycated 
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Fig. 2. Schematic representation of potential pathway leading to AGE 
formation. The abbreviations given above are represented as, 
GLO=glyoxal; MGO mcthylglyoxal; 3-l)G .l-dcoxygkicosonc: 
CML=carboxymethyl-lysine (Turk, 2001). 
extracellular matrix, decreased susceptibility to proteolysis, inactivation of 
enzymes, abnormalities of nucleic acid function, and increased immunogenicity 
in relation to immune complex formation (Turk, 2001). 
Glycotoxins (AGE peptides) 
In process of glycation, AGE peptides are released as degradation products, 
which partly occur through proteolysis of the matrix component commonly 
named glycotoxins. Glycotoxins (AGE peptides) are very reactive on entering 
blood circulation. In case they have not been eliminated through the kidneys, 
recirculating AGE peptides can generate new AGE products that react with other 
plasma or tissue components. At this stage, glycation becomes an autonomic 
process, which significantly accelerates the progress of the complication (Turk, 
2001). 
Glycation of human serum albumin 
Serum albumin non-enzymatically reacts with glucose yielding a stable 
glycated form of albumin (Garlick and Mazer, 1983; Shaklai et al., 1984), which 
is elevated in human diabetics (Dolhofer and Wieland, 1980). The incubation of 
HSA with glucose results in its non-enzymatic glycoxidation in a concentration, 
incubation period and temperature dependant manner (Bayness et al., 1984). The 
principal site of glycation of HSA is lys-525, but the lysine residues in positions 
199, 281 and 439 are also sussceptable to glycation. In addition there are six 
more residues that glycate less efficiently (Shaklai et al., 1984). 
The in vitro exposure of protein to glucose results in the non-enzymatic 
covalent attachment of glucose to lysine side chains in a manner that observed in 
vivo (Brownlee et al, 1987). This process also occurs in individuals with normal 
control of plasma glucose concentrations, but HSA is typically three times more 
glycated than the rest of the population in conditions of hyperglycemia (Bourdon 
et al., 1999) where, during periods of poor control of plasma glucose 
concentration, circulating levels of 25 niM glucose have been recorded. The 
interaction of HSA with glucose showed two sets of binding site. The ilrst set 
"Wl^l.Ci'^ik3> 
consists of two sites witli coopcrativity and the second set consists of nine 
identical non-cooperative sited (Moiiamadi-Nejad el ciL, 2002). The non-
enzymatic glycation of FISA induces refolding of globular proteins, accompanied 
by formation of cross-[] structure that may leads glycated albumin into fibrous or 
amorphous aggregates (Bouma, ct al., 2003) which may change its secondary and 
tertiary structure (Coussons, et al., 1997), alter its normal functions (Shaklai et 
al., 1984; Iberg and Fluckiger, 1986J. Compared to the original albumin, AGl^  
molecules are not only larger in size but also have lower isoelectric points and 
carry more negative charges. Both the size and the negative charges of AGEs 
continue to increase over time during incubation (Wu, et al., 1996) and this may 
also changes the recognition of proteins (Bitensky et al., 1989). Abnormalities in 
protein recognition may contribute to the pathological impact of glycation 
(Bitensky e/a/., 1989). 
Free radical biochemistry 
It is believed that life originated as a result of free redical reactions (FRRs), 
selected FRRs play major metabolic roles, causing repeated mutation, and death, 
thereby assuring evolution. Further, life span evolved in parallel with the ability 
of organisms to cope with damaging free radical reactions, hi short, the origin 
and evolution of life may be due to free radical reactions and, in particular, to 
their ability to induce random change (Harman, 2001). 
Oxygen free radicals are believed to be generated by a number of processes 
in vivo, including the 'respiratory brust' of phagocytic cells, metal Ccitalyzed 
substrate autoxidations, mitrochondrial electron transfer and the reduction of 
hydroperoxides (Halliwell and Gutteridgc, 1984). 
Regardless of how and where free radicals are generated (exogcnously or 
intracellular), a rise in the oxidant level has two important effects: damage to 
various cell components and triggering the activation of specific signaling 
pathways NF-KB. E R K , .INK, NAPK, and PKC isoforms (Idris, et al., 2001). 
Reactive oxygen species (ROS) generated during various metabolic and 
biochemical reactions having multifunctional effects that include oxidative 
damage to DNA leading to various human degeneration and autoimmune 
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diseases (Hasan et al., 2003), moreover, also responsible for the elimination of 
invading pathogens (Khan e'cal, 2005) 
ROS encompasses a variety of diverse chemical species including 
superoxide anions (02'~), hydrogen peroxide (H2O2), alkoxyl (RO'), peroxyl 
(ROO), hydroxyl radicals (OH), and hydrochlorous acid (HOCl) (Jackus, 2000). 
ROS are highly reactive and have extremely short half-lives. Most estimates 
suggest that the majority of intracellular ROS production is derived from the 
mitochondria. There are numerous mechanisms for generation of ROS in vivo 
(Emerit e/^/., 1990). 
Superoxide anion radical 
The uptake of one electron by molecular oxygen result in the formation of 
the superoxide anion radical (02"^ )^ (Florence, 1990; Harris, 1992). Superoxide 
radical is a by-product of many of detoxification reactions (Beckman and Ames, 
1998). First, superoxide is a strong base and can therefore abstract protons from a 
variety of the compounds. Second, 02*~ is a potent reducing agent; it can reduce 
quinines reversibly to semiquinones and transition metal ions such as Fe^ ^ and 
Cu ^ into their reduced forms (Fe"^ and Cu^). Third the superoxide ion is a 
nucleophile and may thus readily interact with a number of electrophilic agents. 
System generating 02*" has been observed to kill bacteria, inactivate viruses, 
damage enzymes and membrane and destroy animal cell culture (Fridovich, 
1978;Halliwell, 1981). 
The superoxide radical is generated within aerobic biological systems 
during both enzymatic and non-enzymatic oxidation. It is eliminated by 
conversion to FI2O2 and O2 by superoxide dismutase (Fridovich, 1983; 1986). The 
finding that 02'" is produced by some enzymes and is efficiently scavenged by 
others (McCord and Fridovich, 1968; 1969) led to the view that 02*" is an agent 
of oxygen toxicity. In this view the superoxide dismutases (SODs), which 
catalytically scavenge O2"", serve a defensive role (McCord el al., 1971). 
Hydrogen peroxide and the hydroxyl radical 
Hydrogen peroxide is ubiquitous in the biological systems, formed by the 
divalent reduction of dioxygcn or by dismutation. 
During the stepwise one-electron reduction of molecular oxygen, hydrogen 
peroxide is the second intermediate. It may however also be generated directly 
via a two-electron reduction of molecular oxygen. Hydrogen peroxide is a stable 
molecule that is generated as an end product of a variety of oxidative reactions in 
living cells. It may, infact, act as both as oxidizing and as a reducing agents. In 
presence of transition metals, H2O2 is thought to give rise to peroxyl radicals and 
extreme reactive hydroxyl radicals via the Fenton reaction (O' Brein, 1969) 
II2O2 t-1<e-' /Cu' • Fc^' /Cu^^+ 011 + 011" 
Or through reaction with a multiplicity of other agents (eg. the air pollutants 
NO or NO2) 
NO + H2O2 • OH + HONO 
NO2 + H2O2 • OH + HONOs 
The hydroxyl radicals are a highly reactive oxidizing agent that can react 
with a wide variety of organic molecules. It can abstract a hydrogen atom from 
essentially any hydrogen-carbon bond and under go addition reaction with 
aromatic systems at a reaction rate close to diffusion limit. 
Photolysis is another important way to produce hydroxyl radical. UV 
irradiation is responsible for this reaction that can directly split H2O2 into two 
OH (Masaki el al, 1995; Mazellier et ciL, 2004). 
hv 
H2O2 • "OH + 'OH 
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Singlet molecular oxygen 
Another radical derived from oxygen is singlet oxygen, designated as 'O2. This is 
an excited form of oxygen in which one of the electrons jumps to a superior orbital 
following absorption of energy. Ever since its discovery (Kantsl<y and deBruijn, 
1931), its production by photosensitization reactions (including those involving 
endogenous sensitizer) has been intensively investigated but more recently 
attention has been drawn by studies showing that O2 can also be generated in the 
absence of light for example by a number of enzymatic reaction (Gille and 
Joenje, 1991) or by interaction between superoxide and reduced glutathione 
(Wefcrs and Sics, 1983). Singlet oxygen is also produced during photoxidation of 
variety of biological compounds and xenobiotics (Krinsky, 1977; Krasnovsky, 
1991). It has been established that human leukocytes can generates 'O2 
(Kanofsky el al, 1988). O2 is relatively long lived, with half time in the range of 
4-50 (.ts, so that the diffusion of singlet oxygen is possible with in a radius of 
estimated to be in the range of hundred A° (Schnurigcr and Bourdon, 1968; 
Moan, 1990). Reactions of singlet oxygen are physical and /or chemical (Kasha 
and Khan, 1970; Krasnovsky, 1979), as physical reactivity is characterized by 
photoemissive decay, while the chemical reaction are many fold, including, 
additions to olefins, forming dioxytanes, allylic hydroperoxide, ('ene reaction') 
and endoperoxide, as well as oxide of sulphide or phenol to form sulphoxide or 
hydroperoxidienones (Aubry, 1991). This chemical reactivity is the bases of 
biological damage inflicted by singlet oxygen. 
Autoxidation and glycation 
Glycation is a major source of ROS that is generated by oxidative pathways 
of glycation (Rahbar and Figarola, 2003). Several studies support the idea that 
glycation and oxidation are closely linked processes, glucose autoxidation plays 
an essential role in non-enzymatic glycation of protein. 
In vitro glycated serum albumin showed possible interactions between 
glycation and oxidation (Traverso et al., 1997). Contents of the glycated serum 
albumin are an index of oxidative modification during glycation (Fu et al., 1992). 
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Glycation mediated modifications induced free radicals can cause conformational 
changes which alter its antioxidant properties (Bourdon et al., 1999). 
Glucose exists in equilibrium with their enediol, which can undergo 
autoxidation to form an enediol radical. This radical reduces molecular oxygen to 
generate the superoxide radical and becomes oxidized itself to a dicarbonyl 
ketoaldehyde that reacts with protein amino groups forming a ketoamine. 
Kcloamine arc similar to, although more reactive, than Amadori products and 
participate in AGE formation (Ahmed, 2005). 
In hyperglycemic conditions, most of the carbonyl compounds generated by 
glycation need oxidative steps in their formation. The protein dicarbonyl 
compounds can participate in AGE formation and referred to as glycoxidative 
products (Liggins and Furth, 1997). 
Free radicals and glycation (also called glycosylation) are central to chronic 
diseases, degeneration and aging. One important source of free radicals is 
advanced glycation end products (AGEs) resuhing from non-enzymatic glycation 
and oxidation of proteins and lipids (Thomas et al., 2005). 
There is ample evidence that ageing, and thus life span, correlate with free 
radical generation and antioxidative defense as well as with advanced glycation 
end products. Most chronic diseases are also associated with free radicals and 
AGEs (Harman, 1984). Overproduction of free radicals accelerates cell ageing 
and is counteracted by antioxidants. The analysis of the mechanism generating 
free radicals and of the reaction of AGEs with cellular metabolism opens new 
avenues for the delaying of the development of chronic diseases such as 
atherosclerosis and neurodegenerative disease (Giardino et al, 1998). 
For a number of age-associated diseases, there is evidence of an association 
with free radicals and AGEs. Table 1 lists these diseases (Stachelin, 1997). 
Table 1: Age-associated diseases tliought to be related to free radicals and 
AGEs 
• Atherosclerosis 
• Cancer 
• Complications of diabetes 
• Cataract 
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• Alzheimer's disease 
• Parkinson's disease 
• Amyotrophic lateral sclerosis 
Diabetic individuals may exhibit elevated levels of iron and free copper 
ions (Cutler, 1978; Mateo et al, 1978), which in the presence of glycated proteins 
in vitro have been shown to generate free radicals (Hunt, 1994). The 
accumulation of glycated material in tissues that contain free copper ion, 
contribute to the generation of free radical mediated damage. These highly 
reactive species are capable of causing oxidative degradation of protein in vitro 
(Hunt et ah, 1994; Smith et al, 1992). The formation of a-dicarbonyl compounds 
is known to be an essential step for the cross-linking of proteins and subsequent 
free radical generation (Rahbar and Figarola, 2003). Methylglyoxal is increased 
5-6 fold; in adult onset, non-insulin dependent diabetes mellitus, 2-3 fold. In the 
presence of oxidative stress, glycation of proteins by methylglyoxal is enhanced. 
This may underlie the link of glycation and oxidative stress with diabetic 
complications, and may also contribute to pathological processes of ageing 
(Harman, 1998). 
Reactive oxygen species and protein oxidation 
Organic free radicals and related eletrophilic metabolite can bind covalently 
to cellular proteins. Amino acids can undergo oxidative damage if they interact 
with oxygen free radicals. Even peptide bonds can be subject to oxidative 
modification by reactive oxygen species. The consequence of such oxidative 
protein modification, in general, is a loss of physiological function, as in the case 
of covalent binding of reactive organic metabolites to proteins (Bradford and 
Allen, 1997). As free radicals are capable of initiating chain reactions, cross-
linking of soluble and/ or membrane-bound proteins, yielding larger aggregates. 
The direct consequence is a change in higher order structure of the protein (e.g., 
in the quaternary structure), which, in turn, results in a loss of biological function 
(Adams et al, 1999; Schoonover, 2001; Dhalla et al, 2000). 
As another extracellular event that may mark protein for complete 
intracellular proteolysis, we have studied the action of autoxidizing sugars on 
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some soluble proteins. Partly consequent on radical generation, proteins are 
glycosylated. Protein fragmentation takes place, with BSA as target protein, using 
glucose and glyceraldehyde autoxidizing for one to eight days (Wolff and Dean, 
1987). 
Elevated radical flux lead to an increased rate of proteolysis of bulk of long 
half-life proteins in cultured cells (Vince and Dean, 1987) and of mitochondrially 
synthesized proteins (Dean and PoUak, 1985). A greater acceleration of 
intracellular protein degradation after radical attack can be observed in 
erythrocytes (Davis, 1986). 
Thus protein damage by radicals is critical in many biological processes. 
This damage may lead to functional inactivation (Willson, 1983), but usually the 
inactivated proteins are degraded, so that proteolysis forms a secondary defence. 
However, when the target proteins are critical for rapid homeostatic mechanisms 
(as in the case of transport proteins) or when the proteolytic defence and/or other 
antioxidant defences are overwhelmed, toxic events may ensue. 
Antioxidants 
Antioxidants are key line of defence capable of scavenging free radicals by 
preventing radical formation, intercepting radicals from further activity 
(Cotgreave et al, 1998). Antioxidant defences are primary and secondary. The 
defences that directly scavange, H2O2 and "OH are known as primary antioxidant 
defence. Secondaiy antioxidant defences consist of the repair mechanisms that 
act on biomolecules that have undergone oxidative damage. 
The major endogenous antioxidants are: 1) superoxide dismutase (SOD) 
which removes O2 ~", catalase that converts H2O2 to water (H2O) and O2, and 
glutathione peroxidase, which helps with H2O2 removal and prevents hydroxyl 
radical ("OH) formation (Fig. 3) (HaUiwell and Gutteridge, 1999). Lipoic acid 
has the unique ability to regenerate several other antioxidants such as vitamin E, 
vitamin C (Packer and Coleman, 1999). Vitamin C, the major plasma antioxidant, 
is a scavenger of many ROS and reactive nitrogen species, and is capable of 
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Fig. 3. Schematic representation of antioxidant activity of SOD, catalase and 
glutathione (HalHwell and Gutteridge, 1999). 
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regenerating tocopherol from its radical (Halliwell and Gutteridge, 1999; 
Maxwell, 1995). Metal chelators DETAPAC and EDTA sequester the trace 
amounts of transition metal and hence inhibiting oxidation (Wolff and Dean, 
1987). Benzoic acid is also a hydroxyl radical scavenger, which inhibits protein 
fragmentation (Hunt et ciL, 1988). There are numerous other dietary sources of 
antioxidants (McDermott, 2000). 
Autoimmunity 
The lack of an immune response to self when responses to environmental 
antigens are retained is due to immunological tolerance. The role of tolerance, or 
lack of tolerance, is important to the understanding of aiitoimmune diseases and 
transplantation immunobiology (Goldsby et al, 2003). A loss of natural tolerance 
(to self) imderlies all autoimmune diseases. Many more individuals develop 
autoimmune phenomena than autoimmune disease. Immune-mediated (Type I) 
diabetes results from an organ-specific autoimmune-mediated loss of insulin-
secreting p cells. This chronic destruction process involves both cellular and 
hormonal components detectable in the peripheral blood, months or even years, 
before the onset of clinical diabetes (Kukreja and Maclaren, 1999). 
hi order to elicit an immune response, a molecule must be recognized as 
nonself by the biological system. When an antigen is introduced into an 
organism, the degree of immunogenecity depends on the degree of its 
foreignness, generally the greater the phylogenetic distance between two species, 
the greater the structural disparity between them. Bovine serum albumin is 
strongly immunogenic when injected into rabbit (Goldsby et al., 2003) 
Anti-HSA antibodies have been observed in diabetes (Eilat et al, 1981), a 
five fold greater occurrence than in nondiabetic persons (Gregor et al., 1986). 
Proteins containing AGEs are highly immunogenic and CML is one of the major 
epitopes recognised by anti-AGE antibodies (Reddy ct al., 1995; Ikeda et al., 
1996). The presence of AGE-antibodies in the serum of streptozotocin-diabetic 
rats as well as in a small number of diabetic patients have been reported 
(Shibayama et al., 1999) AGE can exert their immunogenicity, demonstrate that 
presence of AGEs-immune complexes (AGE-IC) in the diabetic patients that may 
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play a role in the artherogenesis (Turk et ah, 2001). Interactions of AGE 
autoantibodies with AGEs as a continuously produced antigen result in the 
formation of AGE-ICs that may play role in diabetic complications (Jakus and 
Rietbrock, 2004). The analysis of the frequency distribution profile shows that 
14% of the diabetic subjects display significant antibody binding to AGE-HSA 
than the control subjects (Vay et ai, 2000). 
Diabetes mellitus 
Diabetes is growing worldwide at an ever-increasing pace. The latest WHO 
estimate for the number of people with diabetes worldwide in the year 2000 was 
177 million, which is expected to increase to 300 million by 2025. Around 4 
million deaths per year are caused due to conditions directly or indirectly 
associated with diabetes. 
Diabetes mellitus (DM) is a group of metabolic diseases characterized by 
hyperglycemia resulting from defects in insulin secretion, insulin action or both. 
In DM low insulin levels prevent cells from absorbing glucose. As a result, 
glucose builds up in the blood. When glucose-laden blood passes through the 
kidneys, all the excess glucose cannot be absorbed. This excess glucose spills 
into the urine, accompanied by water and electrolytes; ions required by cells to 
regulate the electric charge and flow of water molecules across the cell 
membrane. This causes frequent urination to get rid of the additional water drawn 
into the urine (polyurea); excessive thrust to trigger replacement of lost water 
(polydipsia); and hunger to replace the glucose lost in urination (polyphagia) 
(Alvin, 2005). 
A wide spectrum of pathogenic processes is involved in the development of 
diabetes mellitus, which may range from autoimmune destruction of beta cells to 
the development of insulin resistance. The major risk factors of diabetes mellitus 
are age, obesity, lack of exercise, along with a strong genetic predisposition. A 
strong HLA association with some forms of the disease along with some specific 
antibodies has also been identified (Alvin, 2005). 
Diabetes mellilus was broadly classified into two major types. 
Type I diabetes mellitus 
Type 1 or insulin dependent diabetes mellitus, also known as Juvenile onset 
diabetes mellitus is characterized by an absolute deficiency of insulin where the 
patient is totally dependent on an exogenous source of human insulin, hi over 
90% of the cases Type 1 diabetes mellitus is immune mediated and in less than 
10% of the cases it is idiopathic. It usually occurs in younger age group with 
highest incidence in 10-14 years age group. Improper glucose metabolism causes 
an increase in the blood levels of ketone bodies making the patient very prone to 
ketosis. The incidence of Type 1 diabetes shows little bias upto 15 years of age, 
but more males are diagnosed in early adult life. The lower prevalence of lAA in 
adolescent females implies sex specific modulation of the autoimmune process 
during puberty (Williams et ciL, 2003). 
Immune mediated diabetes results from a cellular mediated destruction of the 
P-eells of the islets of langcrhans of the pancreas (Atkinson and McLaren. 1994). 
A number of antibodies have been detected as the markers of autoimmune 
diabetes. These include islet cell autoantibodies (ICA), insulin autoantibodies 
(lAA) (Atkinson et ciL. 1992) GADf,? autoantibodies (Jun et al., 2002), antibodies 
to tyrosine phosphatases IA-2 and IA-2/? (Lan et al.. 1996; Lu et ciL, 1996). 
Even in the presence of the above predisposing factors the pathogenic 
process might not get initiated. Detailed studies have shown that a toxic or 
infectious insult is required for triggering the autoimmune destruction of P-cells 
of pancreas. Coxsackie-B virus, mumps virus and congenital rubella and 
cytomegalovirus have been shown to be related to Type 1 diabetes in this regard 
(Forrest et al., 1971; King et al., 1983; Karjalainen el al, 1998; Pak et al, 1988). 
MolecuUrr mimicry has been closely linked to Type 1 diabetes mellitus in this 
respect where an autoimmune response is developed either against pancreatic 
antigen or against molecules of B cells resembling the viral protein. 
Type II diabetes mellitus 
Type II or non-insulin dependent diabetes mellitus, also known, as adult 
onset diabetes mellitus is the most common form of the diabetes mellitus. It is 
characterized by hyperglycemia secondary to insulin resistance and insulin levels 
that may be normal or even raised (Defronzo el al., 1979; Turner et al., 1979; 
Koltcrman et al., 1981). A heterogenous group of factors is involved in its 
pathogenesis. Obesity has been a strong predisposing factor for the development 
of insulin resistance and hence Type 2 diabetes mellitus ( Bogardus et al., 1985; 
Olefsky et al., 1982). Moreover, visceral obesity and not subcutaneous 
disposition of fat has been held responsible for giving rise to insulin resistance 
(Kisscbah et al., 1982). Lack of physical activity and increasing age has also been 
the precursors of this form of disease. Genetic predisposition is also a strong 
predisposing factor (Herman e( al., 1994; Bryne et al., 1996). 
Type II DM has a strong genetic component, major gene that predisposes )'et 
to be identified, but it is clear that inheritance is polygenic and multifactorial. The 
concordance of Type II DM in identical twins is between 70 - 90%. Individual 
with a parent with Type II DM have raised risk of diabetes; if both parents with 
Type II DM, the risk is approximately 40%. 
Environmental factors (examples, nutrition and physical activity) further 
modulate phenotypic expression of the disease. Genetic defect in insulin secretion 
or action may not manifest itself unless an environmental event of another 
genetic defect such as obesity is superimposed (Shervin, 2001; Alan, 1998). 
Type II DM is characterized three pathophysiologic abnormalities: 
1- Impaired insulin secretion 
2- Peripheral insulin resistance 
3- Excessive hepatic glucose production 
In early stages P-cells compensate by increase in insulin production. So 
glucose tolerance remains normal despite insulin resistance. Insulin resistance 
and compensatory hyperinsulinemia progresses, the P-cells in certain individuals 
arc unable to sustain the hypcrinsulincmic state. A further decline in insulin 
secretion and an increase in hepatic glucose production leads to overt diabetes is 
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a predominant feature and results from combination of genetic susceptibility and 
obesity. 
The pathogenesis of insulin resistance is currently focused on Pl-3 kinase 
signaling defect, which reduces translocation of GLUT 4 to the plasma 
membrane. Another emerging theory proposes that increased levels of free fatty 
acids, a common feature of obesity, may contribute to pathogenesis. Free fatty 
acids can impair glucose utilization in skeletal muscles, promote glucose 
production by the liver and impair P-cell function. 
The diabetes preventive programme demonstrated that intensive changes in 
lifestyle (diet and exercise for 30 min/day five times in a week) in individual with 
IGT prevented or delayed the development of Type II diabetes by 58 percent 
(Alvin, 2005). 
Albumin in diabetes mellitus 
In fact, only a small number of factors are known to result in the variation in 
serum albumin. The alteration in the structure of albumin due to uncontrolled 
hyperglycemia causes vascular complication (Bourdon et al., 1999). Its level 
decreases about 30-40% in diabetes mellitus (Woodside et al., 1998). Moreover. 
in diabetes the detection of an increase in albumin urinary excretion is a marker 
of some disease and disfunction of kidney (Keen and Chiouverkis, 1963: 
Howthorne, 1989). Alteration of redox state of HSA in patients with diabetes 
mellitus may be the important parameter for the pathogenesis of the disease, as 
oxidized form increased in diabetic patients (Suzuki et al., 1992: Oettl et al., 
2005). Glycated HSA increases in the diabetic sera which is transportated into 
renal glomerulus, induce an increase in Type IV collagen production and a 
decrease in proliferate capacity by mesangial cells (Wolff e/ al., 1991). 
Advanced glycation end-products in the pathogenesis of diabetic 
complications 
In summaiy, AGE products are important mediators of diabetic secondaiy 
complications and age-related diseases. 
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Diabetic retinopathy 
It is characterized by abnormal vessel development leading to haemorrhages. 
ischaemia and infcrctions. Specific morphological and functional changes include 
basement membrane thickening, loss of pericytes and increased permeability 
(Chappcy et al, 1997). Accumulation of AGE might contribute to this state of 
vasculopathy by increasing retinal endothelial cell permeability resulting in 
vascular leakage (Vlassara et al., 1994). 
A study comparing post-mortem human retinas between diabetic subjects 
with background and prolifirative retinopathy and non-diabetic retinas (Murata et 
al.. 1997), none of the control subjects showed CML immunoreactivity. In vitro 
studies have showed that AGE modification of retinal basement membrane 
results in reduced retinal pericyte proliferation but increased retinal endothelial 
cell proliferation. These effects are observed in diabetes and w ith AGE effects on 
nitric oxide depletion, reactive oxygen production and changes in vessel 
elasticity, could explain AGE effects on microvascular structure and function 
(Brownlee, 2000). 
Diabetic nephropathy 
Persistent hyperglycemia has a central role in the development of diabetic 
nephropathy that is clinically manifested by proteinuria progressing to renal 
insufficiency, and histopathologically by mesangial expansion and glomerular 
basement membrane thickening. A possible link between elevated glucose level 
and diabetic nephropathy resides in the glycation process producing AGEs. This 
modification can impair the original function of either protein and may affect 
normal processes of turnover and clearance (Monnier et al.. 1992; Berg et al.. 
1997). 
Circulating serum AGE level is markedly increased in patients with diabetes 
and renal insufficiency. Serum AGEs include both serum proteins that have been 
modified by advanced glycation and low molecular weight AGE peptides 
(Makita el al., 1994). Using specific immunoassay, serum AGE peptide levels 
have been found to correlate with renal function, hi normal controls, AGE 
peptide clearance has been estimated to be 0.72 ml/min. Diabetic persons with 
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normal glomerular filtration rate can clear AGE peptides at the same rate. 
However, progressive loss of renal function is associated with increasing 
circulating AGE peptide levels. In these patients, AGE peptides persist at up to 8-
fold normal level (Turk, 2001). 
Diabetic atherosclerosis 
It has also been well documented that lipoproteins are deeply involved in the 
atherogenic process. Diabetes can lead to several lipoprotein modifications that 
can affect their interaction with arterial wall cells, thereby contributing to the 
increased risk of atherosclerosis. Glycation of apolipoproteins in all classes of 
circulating lipoproteins has been found in diabetes. Approximately 2% to 5% of 
apo B in the plasma of diabetic persons are glycated, compared with about 1 % in 
the plasma from nondiabetic control subjects (Turk, 2001). Reactive AGE 
peptides have been experimentally shown to rapidly promote AGE-LDL 
formation in vitro, indicating that glucose may not be the most proximal reactant 
capable of producing AGE-LDL in vivo. AGE lipoproteins like other advanced 
glycation modified proteins, bind to specific receptors on macrophages and other 
cell types, and can stimulate the release of cytokines and growth factors which 
may play a role in atherogenesis (Lopes-Virella et ai, 1988; Vlassara, 1996). 
Thus, a reduction in the level of glycation of lipoproteins as well as of the arterial 
wall extracellular matrix might alter the interaction of lipoproteins with the 
matrix and reduce their retention in the arterial wall where they are able to exert 
their atherogenic damage. 
ROS in diabetes mellitus 
The putative role of ROS in the development of diabetic complications has 
been investigated for several decades (Baynes and Thorpe, 1999; Oberley, 1988; 
Ceriello et ai, 2000). The level of ROS is increased in hyperglycemic condition, 
which may be closely associated with diabetic complications (Palm et al., 2003). 
It is also described that the increased release of superoxide anions (02'~) from the 
uterine arteries of diabetic patients due to enhanced 02*~ production in smooth 
muscle cell than the endothelial cells. The overproduction of ROS lowered 
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antioxidant defense and alterations of enzymatic pathways in humans with poorly 
controlled diabetes mellitus (Jakus, 2000). 
Rheumatoid arthritis 
Rheumatoid arthritis (RA) is inflammation of the joints along with the 
production of a number of autoantibodies (Newkrik et al., 2003). In many part of 
the world the disease is called rheumatism. It is named after the town where it 
first appeared. It can be caused by bacteria, virus, by a disruption of body 
chemistry or by high stress. A predominant feature of synovitis in rheumatoid 
arthritis (RA) is the development of a hypertrophic, oedematous and highly 
vascularized so-called pannus-like tissue that progressively invades and degrades 
adjacent cartilage and bone (Gay et al., 1993; Firestein, 1996; Pap et al., 2000). 
This tissue, which originates from the synovial lining layer of affected joints, 
consists of synovial fibroblasts (SFs), synovial macrophages and various 
infiltrating inflammatory cells such as activated T and B lymphocytes. The joint 
destruction is mediated by matrix-degrading enzymes released predominantly by 
activated SFs similar to mechanisms observed in malignant disease (Muller-
Ladnere^o/., 1998). 
Long term outcome predictors, such as the presence of rheumatoid factors 
(Eberhardt et a/., 1990; Van Schaardenburg et al, 1993) and the QKRAA shared 
epitopeon the HLA-DR/J chain (Wagner et al, 1997; Weyand et al, 1992). 
Albumin in rheumatoid arthritis 
Albumin is the largest transportable source of nitrogen and energy in the 
body and can be used to carry drugs to cells with a high nitrogen and energy 
demand such as the cells involved in the synovial inflammation of RA (Wunder 
et al, 2003). Recently shown that methotrexate-HSA (MTX-HSA) is more 
effective than equivalent concentrations of MTX in preventing CIA (Wunder el 
al, 2003). In addition to synovial fibroblasts, which we previously identified as 
target cells for albumin-mediated drug delivery in RA, monocytes, granulocytes 
and T and B lymphocytes, which all were shown to play a significant role in the 
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pathophysiology of this disease, might be further targets of this novel treatment 
approach. (Fiehn et al., 2004). Albumin conjugates are internalized into cells by 
endocytosis. 
The potential use of albumin as a drug carrier in RA is favoured by the facts 
that the permeability of the blood-joint barrier for albumin in inflamed joints is 
markedly increased and patients with active RA, similar to cachectic cancer 
patients. A complex of human serum albumin and rabbit IgG anti-HSA 
antibodies is used as antigen for RF (Kleveland et ai, 1988). Moreover, MTX-
HSA is superior to MTX in the suppression of tumour growth and development 
of arthritis in rodent models (Fiehn et al., 2004). 
Glycation and rheumatoid arthritis 
Rheumatoid arthritis (RA) is characterized by persistent articular and 
systemic inflammation, along with the production of a number of autoantibodies. 
Antibodies directed toward the Fc portion of the IgG molecule or rheumatoid 
factor (RF) are detected in approximately 70% of patients with RA. 
During inflammation proteins can be damaged by non-enzymatic 
glycoxidation (Singh et al, 2001; Ulrich and Cerami, 2001). AGE-damaged 
proteins are increasingly being implicated in other diseases such as 
atherosclerosis, amyloidosis, aging (in particular, cartilage and the lens of the 
eye) (Ulrich and Cerami, 2001), also in RA (Chen et al., 1998; Furumitsu et al, 
2000; Miyata et al, 1998) and osteoarthritis (Torchiana et al, 1998; Pokharna et 
al, 1995). The cross-links that form in cartilage due to pentosidine, which cause 
the typical yellowing (Monnier et al., 1984), are thought to contribute directly to 
the joint pathology and increase in urinary AGE detected in patients with 
osteoarthritis or RA. Such increases may also reflect cartilage degradation. 
Not only cartilage but also antibodies can be damaged during inflammation. 
Previous studies have shown that AGE-damaged IgG can be detected in patients 
with arthritis of long duration (Ligier el al, 1998; Lucey et al, 2000; Newkirk et 
al, 1998). AGE can be detected on both the heavy and light chains of IgG (Ligier 
et al, 1998; Tai and Newkrik, 2000; LapoUa el al, 2000). Studies indicated not 
only that IgG-AGE could be detected in patients with RA, but also that 
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approximately 30^0% of RF-positive patients mounted an immune response to 
IgG-AGE. One possible explanation for the origins of these antibodies and the 
link to RFs is that RF-positive B-cells could act as antigen-presenting cells for the 
damaged IgG and thus stimulate the anti-IgG-AGE response (analogous to 
epitope spreading) by other antigen-selected B-cells that express a surface 
immunoglobulin specific for the IgG-AGE. hi a previous study of RA patients 
with long standing disease (Lucey el al., 2000), the anti-IgG-AGE antibodies 
were found to correlate significantly with measures of disease activity whereas 
RFs did not. 
Patients with early disease, anti-IgG-AGE was found to correlate 
significantly with the swollen joint count and thus appears to be a marker of 
disease activity. 
ROS in Rheumatoid arthritis 
Recent studies indicated that increased oxidative stress and/or defective 
antioxidant status contribute to the pathology of rheumatoid arthritis (RA) 
(Karatas et al., 2003). The study showed raised levels of malondialdehyde and 
low levels of endogenous antioxidants in patients of rheumatoid arthritis. Plasma 
catalase had also been reported to be significantly lower in patients with RA 
(Kamanli et al., 2004). Another study reported impaired glutathione reductase 
activity in synovial fluid in rheumatoid arthritis (Bazzichi et al., 2002). In active 
R (De Leo et al., 2002) and juvenile idiopathic arthritis (Gotia et al., 2001), 
increased oxidative stress and decreased levels of antioxidants have been 
reported. An epidemiological study (Knekt et al., 2002) suggested that low 
selenium status may be a risk factor for rheumatoid factor-negative RA and low 
a-tocopherol status may be a risk factor for RA independently of rheumatoid 
factor status. Another study (Kerimova et al., 2002) suggested that ROS 
generation could be decreased via inhibition of an enzyme (thioredoxin 
reductase) by gold thioglucose in RA. Overall it is well evident that there is 
increased state of oxidative stress in RA, which proposes the use of antioxidant 
supplementation in such patients. 
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Objective of the present study 
Advance glycation end products produced by covalent interaclion between 
sugar and free amino groups of proteins along with free radical production arc 
known to be involved in the pathogenesis of several diseases like diabetes and 
rheumatoid arthritis. These free radicals and glycation end products are known to 
cause severe protein damage resulting in major structural alterations, which is 
implicated either through their functional disability or these being highly 
immunogenic. 
Thus based on earlier observations the present study was planned to study 
the effect of glucose and oxygen reactive oxygen species (OH) on HSA. as it 
being most abundant protein in human blood. It was first modified with glucose 
and the glycated HSA was then subjected to hydroxyl radical ( OH), generated b}' 
UV irradiation in presence of hydrogen peroxide. Native and modified HSA were 
then characterized by various electrophoretic, spectral, circular dichroism 
spectropolarimetry, colorimetric and thermal denaturation studies. 
Furthermore, antigeneeity of native and modified HSA was probed by 
inducing antibodies in rabbits. Both native and modified HSA induced high titer 
antibodies. However, glycated HSA and ROS-glycated HSA were found to be 
more immunogenic in comparison to its native form, as assessed by direct 
binding ELISA. The specificity of induced antibodies was evaluated by 
competition ELISA and gel retardation assay. 
The serum of patients with diabetes and rheumatoid artluitis contains a 
bewildering variety of autoantibodies that react with a variety of protein and 
nuclear antigens. In order to assess the possible role of glycated HSA and ROS-
glycated HSA epitopes in the aetiology these diseases, sera from diabetic and 
rheumatoid arthritic patients were investigated for the presence of antibodies to 
native and modified HSA. The polyclonal anti-native and modified HSA 
antibodies could be used as probe to detect and quantitate protein modified with 
glucose and hydroxyl radical in healthy and disease. 
More sensitive methods of quanfitation of HSA modified with glucose 
and/or OH might serve as a better diagnostic and prognostic marker of disease 
process. 
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MATERIALS 
Human serum albumin (USA), dinilrophenylhydrazine (DNPH), Milliporc 
filler (0.2 i-m-i). catalase. Protein A-Agarose (2.5 ml pre-packed column). 
mannitol. dicthylenc triamincpentaacelicacid (DCTAPAC). 
elhylenetetradiaminetetraacctic acid (EDTA), aminoguanidine. 
Nilrobluetelrazolium (NBT), superoxide dismutase (SOD), bovine serum albumin 
(BSA), anti-human/anti-rabbil IgG-alkaline phosphatase conjugate, p-nitrophenyl 
phosphate. Coomassie Brilliant Blue G-250 and R-250. sodium dodccyl sulphate 
(SDS), Tween 20, Freund's complete and incomplete adjuvants, and agarose 
were from Sigma Chemical Company, U.S.A. D-glucose was obtained from 
Merck (hidia). 2,4,6-trinitrobcnzenesulphonic acid (TNBS) were purchased from 
SRL Chemicals (hidia). Sephacryr^'S-200 HR was purchased fr om Pharmacia 
Fine Chemicals, Sweden. Folin-Ciocalteau reagent and Blue Dextran 2000 were 
purchased from Center for Biochemical Technology, New Delhi. Absolute 
ethanol was obtained from BDIl Laboratory Supplies, England. Polystyrene 
microtitre flat bottom ELISA plates having 96 wells (7 mm diameter) were 
purchased from NUNC, Denmark. Acrylamide, ammonium persulphate, 
bisacrylamide. N.N,N'N'-tetramethylethylenediamine (TEMED) were from Bio-
Rad Laboratory U.S.A. Hydrogen peroxide, isoamyl alcohol, methanol, phenol 
and glacial acetic acid were from Qualigens, India. Diphenylamine was 
chemicalh' pure. All other reagents/chemicals were of the highest anahtical 
grade a\'aiiable. 
Equipments 
Shimadzu UV-240 spectrophotometer equipped with thermoprogrammer 
and controller, .lASCO .1-810 spectropolarimeter, Hitachi F20()o spectrofluorometer 
(.Japan). ELISA microplate reader (Labsystem Multiskan, Finland), Elico pi I 
meter LI-120, Ultraviolet lamp (Vilbcr Lourmat, France), Avanti 30 table top 
high speed refrigerated centrifuge (Beckman. U.S.A.), polyacrylamide gel 
electrophoresis assembly (Bio-Rad, U.S.A.) were the major equipment used in 
this stud\. 
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Collection of sera and blood samples 
Normal human sera were obtained from healthy subjects. Diabetes 
mellitus patients and rheumatoid arthritic patients' sera were obtained from 
outdoor and indoor patients of the Department of Medicine, Department of 
Microbiology and Department of Orthopadics, Jawahar Lai Nehru Medical 
College Hospital, A.M.U., Aligarh. Serum samples were decomplcmenled at 
56°C for 30 min and stored in aliquots at -20°C with 1% sodium azide. 
Methods 
Protein estimation 
Protein was estimated by the methods of Lowry el al., (1951) and Bradford 
(1976). 
Protein estimation by Folin's-phenol reagent 
The protein estimation by this method utilizes alkali (to keep the pH high). 
Cu"^ ions (to chelate proteins) and tartarate (to keep the Cu"^ ions in solution at 
high pH). 
(a) Folin-Ciocalteau reagent 
The reagent was purchased from Centre for Biochemical Technology, New 
Delhi and diluted 1:4 with distilled water before use. 
(b) Alkaline copper reagent 
The components of alkali copper reagent were prepared as follows: 
(i) 2 percent sodium carbonate in 100 mM sodium hydroxide 
(ii) 0.5 percent copper sulphate in 1.0 percent sodium potassium tartarate. 
The working reagent was prepared fresh before use by mi.xing 
components (i) and (ii) in the ratio of 50:1. 
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(c) Procedure 
I'o 1.0 ml of protein sample was added 5.0 ml of alkaline copper 
reagent and incubated for 10 min. at room temperature. 1.0 ml of working 
Folin-Ciocalteau reagent was added and the tubes were read at 660 nm after 
30 min. The concentration of protein in unknown sample was determined 
from a standard plot of bovine serum albumin. 
Protein estimation by Bradford (dye-binding) method 
This assa} is based on color change observed when Coomassie Brilliant 
Blue G-250, an acidic dye, binds hydrophobically to protein having positively 
charged groups (Bradford, 1976). hi the environment of these positively charged 
groups, protonation is suppressed and a blue color is observed (Xma\ =595 nm). 
(a) Dye preparation 
One hundred microgram of Coomassie Brilliant Blue G-250 was dissolved 
in 50 ml of 95% ethanol and was added 100 ml of 85% (v/v) orthophosphoric 
acid. The resulting solution was diluted to a final volume of 1.0 litre and filtered 
through a Whatman No.l filter paper to remove undissolved particles. 
(b) Protein assay 
To 1.0 ml solutions, containing 10-100 fig protein, 5.0 ml of dye solution 
was added and the contents were mixed by vortexing. The absorbance was read at 
595 nm after 5 min, against a blank reagent. 
Modification of HSA by glucose 
For the preparation of glycated HSA, Img/ml of HSA (15.15 p.M), in 20 
mM PBS, pH 7.4, with 0.05 M D-glucose filtered through 0.2 |im Millipore filter 
was incubated for 10 weeks at 37°C in dark under sterile conditions in capped 
vials. Solution of HSA without glucose served as control. After incubation, the 
solutions were extensively dialyzed against PBS and stored at -20°C before use. 
Protein coneentration was measured by Bradford method (Bradford, 1976). 
IgG, BSA and poly-L lysine were also glycated similarl}' as mentioned 
above. 
Modification of glycated HSA by reactive oxygen species 
Aqueous solution of glycated HSA in PBS. pH 7.4 was irradiated under 254 
nm light for 30 min at room temperature in the presence of hydrogen peroxide 
(10 mM). Under this condition the major radical generated would be 'OH. Excess 
of hydrogen peroxide was removed by extensive dialysis against PBS. pH 7.4. 
Glycated IgG, BSA and poly-L lysine were also modified by ROS as 
mentioned above. 
Polyacrylamide gel electrophoeresis 
Electrophoresis was performed essentially according to the method of 
Laemmli (1970) using the slab gel apparatus manufactured by Biotech, hidia. 
Stock solution of 30% acrylamide containing 0.8% bisacrylamide was mixed in 
appropriate proportion to give the desired percentage of gel. It was then poured 
into the mould formed by iwo glass plates separated by 1.5 mm thick spacers. 
Bubbles and leaks were avoided. A comb providing a template for seven wells 
was quickly inserted into the gel film and polymerization allowed to occur. After 
15-20 min, the comb was removed and the wells were cleaned, overlaid with 
running buffer. Samples containing 15-35 \xg protein mixed with equal volume of 
sample buffer (containing 10% v/v glycerol, 0.06 M Tris HCl, pH 6.8 and traces 
of bromophenol blue as tracking dye) were applied to the wells. Eletrophoresis 
was performed at 50 V in the eletrophoresis buffer containing 0.025 M Tris and 
0.2 M glycine until the tracking dye reached the bottom of the gel. 
Sodium dodecyle sulphate polyacrylamide gel electrophoresis 
Sodium dodecyle sulphate (SDS) was performed by the Tris-glycine buffer 
system of Laemmli (1970) using slab gel electrophoresis apparatus. Concentrated 
stock solution of 30% acrylamidc containing 0.8% bisacrylamidc. 1.0 M Tris (pH 
6.8 and 8.8) and 10% SDS were prepared and mixed in appropriate proportion to 
give the final required percentage. It was poured in the mould formed by two 
glass plates separated by 1.5 mm thick spacers avoiding leaks and bubbles. A 
comb providing a template for seven wells was quickly inserted into the gel 
before the polymerization began. The comb was removed once the 
polymerization was complete and wells were overlaid with the running buffer. 
Protein samples were prepared in the sample buffer containing l%o (w/v) SDS. 
10%) (v/v) glycerol, 0.0625 M Tris HCl, pH 6.8 and traces of bromophcnol blue 
as tracking dye and where required 5%o /^-mercaptoethenol. The samples were 
boiled at 100°C lor 5 min. electrophoresis was performed in electrophoresis 
buffer containing 0.025 M ITis and 0.2 M glycine at 50 V till the tracking dye 
reached the bottom of the gel. 
Staining Procedures 
After the electrophoresis was complete the gels were removed and the 
protein bands were visualized by staining. 
(a) Coomassie brilliant blue staining 
Protein bands were detected by staining with 0.1 % coomassie brilliant blue 
R-250 in 40%o Isopropanol and 10% acetic acid. 
(b) Silver nitrate staining 
The procedure described by Merril et ai, (1982) was followed. After 
electrophoresis the protein bands were fixed by rapidly immersing in a mixture of 
40%) (v/v) methanol and 10% (v/v) acetic acid for one hour with instant shaking. 
The gel was washed with 10% methanol and 5% (v/v) acetic acid twice, each 
time for 15 min to allow the gel to swell to normal size. This was followed by 
incubation in 3.4 mM potassium diehromate solution containing 3.2 niM nitric 
acid for 15 min and washing with distilled water. The washed gel was then 
immersed in silver nitrate solution for 20 min and then again washed with 
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distilled water and transferred to 280 niM solution of sodium carbonate 
containing 0.5% formaldehyde to make the gel alkaline. Ihe reaction was 
stopped after 10 min by transferring the gel to 3% acetic acid solution for 5 min. 
'Ihe gel were washed 4 to 5 times with distilled water and iinally stored in 
distilled water. 
Spectral Analysis 
Ultraviolet absorption spectroscopy 
The ultraviolet absorption spectra of native and modified HSA samples 
were recorded in the wavelength range 200-400 nm on a Shimad/u UV-240 
spectrophotometer. Using a cuvette of 1 cm pathlength. Two hundred fdt> 
micrograms of native and modified HSA in a total volume of 3.0 ml was taken 
for spectral analysis. 
Fluorescence spectroscopy 
Native and modified HSA was analyzed by measuring intrinsic 
fluorescence at 25°C in Hitachi Fioo spectrofluorometer (Japan). To study the 
cumulative effect of tyrosine, tryptophan and phenylalanine the protein was 
excited at 280 nm and the emission was measured over the range of 300-450 nm. 
The fluorescence of tryptophan residue Trp2i4 in native and glycated HSA 
was monitored \\ith excitation at 285 nm and the emission measured over the 
range 290-440 nm (Shaklai el al.. 1984). The concentration of protein samples 
was taken as 100 |.iM. 
Circular dichroisni spectropolarimetry 
CD of native and modified HSA was measured in a Jasco J-810 
spectropolarimeter equipped with a temperature controlled sample cell holder. 
Spectra were recorded with a scan speed of 20 nm/min and with a response time 
of 1 second. Each spectrum was the average of 2 scans. Measurements in the 
range of 200-350 nm were taken using HSA concentration of 2.2 |.iM with a 1 
mm path length cell. For each sample the buffer was used as blank. 
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The results were expressed as mean residual eleclricity (MRC) and 
expressed in deg.cnr.dmor', whieh is defined as 
MRn-e„bs / (10xnx/xCp) 
Where 0 oh-, is the CD in milldcgrcc, n is the number of amino acid 
residues, / is the path length oi' the cell and Cp is the mole fraction. 1 he relati\ 
percentages of the secondary structure elements present were estimated by using 
software based on Yang equation (Chen and Yang, 1971). 
Absorption-temperature scan 
Thermal denaturation analysis of HSA was performed in order to ascertain 
the degree of modification incurred on the HSA by determining mid point 
melting temperature (Tm). Native and modified HSA samples were subjected to 
thermal denaturation on a Shimadzu UV-240 spectrophotometer coupled with a 
temperature programmer and controller assembly (Hasan and Ali. 1990). All the 
samples were melted from 30°C to 96°C at a rate of 1.0°C/min after 10 min 
equilibration at 30°C. The change in absorbance was recorded at 280 nm and 
percent denaturation evaluated with increase in temperature. Percent denaturation 
was calculated as follows: 
AI - A 3 0 
Percent denaturation "= x 100 
Ania\ - A-,() 
Where, Ai = Absorbance at a temperature T°C. 
Anid\ = Final maximum absorbance on the completion of 
denaturation (96°C). 
A30 = Initial absorbance at 30°C. 
Ketoamine estimation by nitrobluetetrazolium 
The native, glycated and ROS-glycated HSA were quantitated by a 
published colorimetric procedure (Mashiba el al., 1992) using NBT with slight 
modification. BSA (10 mg/ml) was incubated with 0.5 M glucose for 90 days at 
37°C in 20 mM PBS. The treatment resulted in complete modification of protein 
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with subsequent formation of ketoamincs (Ahmed and Furth, 1991). Native, 
glycated and ROS-glycated USA samples (50 \i\) were added to the wells ol'96 
well microtitre plates in duplicate. One hundred |.d of NBT reagent (250 (.iM in 
0.1 M carbonate buffer. pH 10.35) was added to each well and incubated at 37°C 
for 2 h. I'hc plate was read in a microplatc reader at 550 nm. I'he amount of 
ketoamine in native, glycated and ROS-glycated HSA samples were calculated 
using standard curve constructed with glycated BSA. 
Determination of protein bound carbonyl groups 
IISA-bound carbonyl groups were estimated by a bublished procedure 
(Levine el al, 1990). Briefly, 200 \x.\ aliquot (containing 0.1 mg of protein) was 
mixed with 400 jil of 7 niM dinitrophenyl hydrazine (DNPH) in 2 M HCl. The 
mixtures were run in duplicate and the control protein samples > e^re devoid of 
DNPH. After incubated for 1 hour at room temperature the DNP-hydrazones 
were precipitated by adding 500 j.d of trichloroacetic acid (4% w/v) and 
centrifuged for 5 minutes at 14,000xg. The pellet was dispersed in ethanol-
eth>lacetate (1:1, v/v), in order to remove unreacted DNPH and centrifuged. 
After four such wash, the pellet was resuspended in 0.6 ml of 6 M guanidinium 
hydrochloride solution in 20 mM phosphate buffer, already adjusted to pH 2.3 
with trifluoroacetic acid. The hydrazones were dissolved completely only by 
freezing overnight at -20°C and thawing. From the solution, 200 \\\ aliquot was 
taken into a microplatc and read at 379 nm by a microplate reader. The results 
were expressed as the number of moles of carbonyl per mole of sample protein 
using a £379 nm= 22000 M"'cm"'. 
Free amino group estimation 
fhe exposed amino groups of native, glycated aiM ROS-glycated HSA were 
determined by the method described earlier (HabefeJ). 1966) with slight 
modiPication. Suitable aliquots of the protein samples wereMissolved in 1 ml of 
0.1 M sodium tetraborate buffer, pH 9.3, was added 25 \A of 0.3 M TNBS and the 
tubes agitated instantly to ensure complete mixing and allowed to stand for 30 
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min at 25°C. Absorbance of the yellow color developed was reeovdcd at 420 nm 
against a reagent blank. Glycine was used as standard amino acid. 
Isolation of albumin from human serum 
Scrum albumin was isolated from normal and diabetic patient's blood 
according to the method described earlier (Tayyab and Qasim. 1990). Briefly, 
blood sample was centrifuged at 1500 x g for 20 min to obtain plasma, which was 
brought to 2.26 M in ammonium sulphate by adding requisite volume of 4.0 M 
ammonium sulphate solution. pH 7.0. The mixture was kept for 12 hr at room 
temperature and then carefully diluted with water and with frequent addition of 
0.5 N H2O2. such that the fmal concentration of ammonium sulphate was reduced 
to 1.9 M and the pH to 4.2. After incubating it for 12 hr at room temperature, the 
precipitate was collected by centrifugation at 3000 x g for 30 min. It was washed 
3 times with 2.2 M ammonium sulphate solution, pH 4.2 and then dissolved in 
0.07 M sodium phosphate buffer, pH 7.4 containing 0.08 M NaCl. The protein 
preparation thus obtained was serum albumin, extensively dialysed against 6 
litres of the 0.07 M sodium phosphate buffer pH 7.4 and stored at 4°C. 
For further purification, 1.0 ml protein samples were applied to a gel 
filtration column (2x60 cm) packed with Sephacryl S-200 (M.W. fractionation 
range 5xl0''-2.5xl0"^ Dalton). After discarding the void volume (45 ml), 
determined by Blue Dextran, the serum albumin was eluted at a rate of one drop 
in 20 sec and thirty six fractions, each of 5 ml, were subsequently collected. 
Comparing the elution profile of commercially available unmodified HSA 
checked the purity of isolated albumin. 
Isolation of IgG by Protein A-Agarose 
Serum IgG was isolated by affinity chromatography on Protein A-Agarose 
column. Serum (0.5 ml), diluted with an equal volume of PBS, pi I 7.4 was 
applied to a column equilibrated with the same buffer. The wash through was 
recycled 2-3 times. Unbound IgCj was removed by extensive washing with PBS, 
pH 7.4. The bound IgG was eluted with 0.58% acetic acid in 0.85% sodium 
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chloride (Coding, 1976) and neutralized with 1 ml of 1.0 M Tris-HCl, pH 8.5. 
Three ml fractions were collected and read at 25! and 278 nm. The IgCi 
concentration was determined considering 1.4 ODiso "" 1-0 mg IgG/ml. fhc 
isolated IgG was dialyzed against PBS, pH 7.4 and stored at -20°C with 0.1% 
sodium azide. 
Immunization Scheme 
The animals (female rabbits) were immunized intramuscularly with 100 |.ig 
each of native and modified HSA, emulsified in Freund's complete adjuvant. 
Subsequent injections were in an incomplete adjuvant. Each animal received a 
total of 500 jig antigen during the course of immunization. Blood was collected 
from marginal vein of the ear. The serum separated from preimmune and 
immunized blood was decomplemented by heating at 56°C for 30 min. Pre-
immune serum was collected prior to immunization. The sera were stored at -
20°C in aliquots with sodium azide as preservative. 
Immunological detection of antibodies 
(a) Immunodiffusion 
Immunodiffusion (ID) was carried out by Ouchtertony double 
immunodiffusion system (Ouchterlony, 1949). Six ml of 1.0% molten agarose in 
PBS, containing 0.1% sodium azide, was poured onto a glass petridish and 
allowed to solidify at room temperature. Wells of 5 mm diameter were cut into 
the hardened gel and an appropriate concentration of antigen and respective 
antiserum were placed in the wells. The petridish was allowed to stand in a moist 
chamber at room temperature for 48-72 hr. The gel was washed with 5% sodium 
citrate to remove non-specific precipitin lines and the result was analyzed 
visually. 
(b) Enzyme-Linked Immunosorbent Assay 
The following reagents were prepared in distilled water and used in 
ELISA. 
Buffers and Reagents 
-^ Tris Buffered Saline (TBS) 
10 niM Tris, 150 mM NaCl, pH 7.4. 
^ Tris Buffered Saline-Tween 20 (TBS-T) 
20 mM Tris. 144 mM NaCl. 2.68 mM KCl pH 7.4. containing 500 1^ 
Tween 20. 
-> Carbonate-Bicarbonate Buffer 
15 mM sodium carbonate. 35 mM sodium bicarbonate, pH 9.6. containing 
2 mM magnesium chloride. 
-^Substrate 
500 |J.g/ml p-nitrophenyl phosphate in carbonate-bicarbonate buffer, pH 
9.6. 
Procedure 
Antibodies were detected by ELISA using polystyrene microtitre plates as 
solid support (Ali and Alam, 2002). 
One hundred microlitres of 2.5 |ng/ml antigen in TBS, pH 7.4. was coated in 
test wells of microtitre plates, incubated for 2 hr at 37°C and then overnight at 
4°C. The antigen-coated wells were washed three times with TBS-T to remove 
unbound antigen. Unoccupied sites were blocked with 150 |.il of 1.5% BSA in 
TBS for 4-5 hr at room temperature. The plates were washed once with TBS-1 
and the antibody (100 |j,l/well) to be tested, diluted in TBS, was added to each 
well. After 2 hr incubation at 37°C and overnight at 4°C, the plates were washed 
four times with TBS-T and an appropriate anti-immunoglobulin alkaline 
phosphatase conjugate was added to each well. After incubation at 37°C for 2 hr, 
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the plalcs were washed four times with TBS-T, three times with distilled water 
and subsequently developed using p-nitrophenyl phosphate substrate. The 
absorbancc was recorded at 410 nm on an automatic microplatc reader, l-^ ach 
sample was run in duplicate. The control wells were treated similarly, but were 
devoid of antigen coating. Results were expressed as a mean of A .^^ i -A conuoi 
(c) Competition ELISA 
The antigenic specificity of antibodies was determined by competition 
ELISA (Hasan et ai. 1991). Varying amounts of inhibitors (0-20 )-ig/ml) were 
mixed with a constant amount of antiserum or IgG. The mixture was mcubated at 
room temperature for 2 hr and overnight at 4°C. The innate complex thus formed 
was coated in the wells. Percent inhibition was calculated using the formula: 
Ainhibiled 
Percent hihibition = 1 - x 100 
'^'•uninhihited 
(d) Band Shift Assay 
For the visual detection of antigen-antibody binding and immune complex 
formation, gel retardation assay was performed (Dixit and Ali, 2004). A constant 
amount of antigen was incubated with varying amounts of IgG in PBS, pH 7.4 for 
2 hr at 37°C and overnight at 4°C. One-tenth volume of 'stop-mix" dye was 
added to the mixture, which was electrophoresed on 5.5% polyacrylamide gel for 
3 hr at 50 mV in SDS-PAGE buffer, pH 7.4. The gels were stained with silver 
staining and than the gel were kept in the distilled water. 
'^:^BSA** 
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Gel electrophoresis pattern of HSA 
Polyacrylamide gel electrophoresis of native HSA, glycated USA and ROS-
glycated USA was performed on 8% gel in the presence of/^mercaptocthanol 
(I'ig. 4). Native HSA showed single band of about 65 kDa. After glycation of 
HSA and and its subsequent ROS modification, a visible difference in 
electrophoretic pattern was found, 'fhe glycated HSA showed broadening of band 
toward high and low molecular weight, more appreciably towards high molecular 
weight showing the formation of high and low molecular weight aggregates. 
ROS-glycated HSA showed decrease in the intensity and broadening of the band. 
Spectroscopic analysis of native and modified HSA 
Ultraviolet absorption spectral studies 
The UV absorption spectra of glycated HSA showed hypochromicity at 
280 nm. The hypochromicity was 43.5%, whereas, ROS-glycated HSA showed 
hyperchromicity at 280 nm to the extent of 32.3% (Fig. 5). However, no peak 
shift was found in both the eases. 
Fluorescence spectroscopy 
The glycated and ROS-glycated HSA samples were characterized for its 
fluorescence emission spectra over the range of 290-450 nm using excitation 
wavelength of 280 nm. As shown in Fig. 6, the emission spectra gave maximum 
intensit) at 310 nm for native HSA, glycated HSA and ROS-glycated HSA. The 
glycated HSA showed decrease, whereas, ROS-glycated HSA showed increase in 
the magnitude of fluorescence intensity. 
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Fig. 4. SDS-polyacrylamidc gel electrophoresis in presence of ^-
mercaptoclhanol of native, glycated and ROS-glycated HSA. 
Sample proteins (10 |.ig) were loaded per lane in 10% 
polyacrylamide gel. Lane 1: protein markers (Mr, 98-14 kDa); lane 
2: native MSA; lane 3; glycated HSA and lane 4: ROS-glycated 
USA. 
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Fig. 5. Ultraviolet absorption spectra of native HS A (~ 
( ) and ROS-glycated HSA (• ). 
-), glycated HSA 
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Fig. 6. Fluorescence emission spectra of native HSA ( ), glycated HSA 
( ) and ROS-glycated HSA ( - • - • - • ) . Excitation wavelength 
was 280 nm. 
Due to its high sensitivity and reproducibility, the level of fluorescence of a 
single tiyptophan residue in the HSA molecule has been chosen as an index of 
conformational changes. Tryptophan specific fluorescence analysis were 
conducted, where both native as well as modified samples of HSA were excited 
at 295 nm. The emission maxima of native, glycated and ROS-glycatcd HSA 
samples were found to be 330, 310 and 321 nm, respectively, indicating a blue 
shift of 20 and 9 nm for glycated HSA and ROS-glycated HSA, respectively. 
There was marked reduction in the fluorescence intensity in glycated HSA, 
whereas, ROS-glycated HSA showed increased intensity as compared to native 
and glycated form of HSA (Fig. 7). The relative quantum yield of glycated HSA 
and ROS-glycated HSA, calculated from the areas of the emission peaks, were 
AGHSA/ANGHSA= 0.31 and ARGHSA/ANGHSA= 0.74 (where NGHSA, GHSA and R-
GHSA represent native, glycated HSA and ROS-glycated HSA, respectively). 
Circular dichroism spectropolrimetry of native and modified 
HSA 
Induction of secondary structural changes on glycation and ROS-glycation 
can be revealed by the biophysical method of circular dichroic spectra. Changes 
in protein conformation were observed in UV CD. spectra of native HSA. 
glycated HSA and ROS-glycated HSA (Fig. 8). In the spectral region of 200-250 
nm, the CD signal of proteins is mainly due to its secondary structure (Hennessay 
et al., 1981; Manavalan, 1993;). The CD spectra obtained for modified HSA and 
native HSA showed significant differences, indicating major changes in the 
secondary structure of both modified HSA samples compared to native HSA. The 
spectrum for both glycated and ROS-glycated HSA also exhibited a potent dip at 
219 nm, inferring a stable /?-sheet structure. The secondary structural details of 
native and modified HSA samples were obtained from software based on Yang 
equation (Chen and Yang, 1971) and are summarized in Table 1. Appreciable 
changes have been observed in a-helix, /i-sheet, random coil and turns in HSA. 
Both modified HSA showed slie,ht decrease in a-helix structure. 
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Fig. 7. Tryptophan fluorescence spectra of native HSA ( ). glycated HSA 
( -) and ROS-glycated HSA ( - • - • - • ) • Excitation wavelength was 
295 nm. 
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Fig. 8. Circular dichroic spectra of native HSA (-
and ROS-glycated HSA (- • - • - ) . 
-), glycated HSA ( ) 
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Table 1 
Secondary structure of native, glycated and ROS-glycated 
HSA observed by circular dichroism spectropolarimetry 
Conformation 
a-helix 
/3-Sheet 
Random coil 
Turns 
Native HSA 
41.3 i 1.08* 
28.4 ±0.94 
11.7 ±0.64 
I8.6±0.76 
Glycated HSA 
39.5 ±0.86 
29.9 ±0.79 
11.4±0.71 
19.2 ± 1.02 
ROS-glycated HSA 
38.01 ± 1.13 
28.83 ± 1.24 
12.01 ±0.68 
21.15±0.89 
* The values are in percent 
Each sample was read in triplicates and the values are mean ± SD. 
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liovvcvcr, P-shect showed increase after giycalion and ROS modification. No 
appreciable changes were observed in tlie random coils for both modified USA 
samples as compared to their unmodillcd form. However, the turns in the 
secondary structure of both modified samples of USA showed gradual increase. 
fhese findings points out structural alterations in HSA and a partial destruction 
of the secondary structure of USA on modifications. 
Thermal denaturation of native and modified HSA 
Thermally induced transitions were measured spectrophotometrically at 
280 nm by heating protein samples at a rate of 1.5°C/min. Melting curves were 
obtained at temperatures from 30.0°C to 96.0°C. The increase in absorbance at 
280 nm was taken as a measure of denaturation. The process was characterized 
by determining the percent HSA in denatured state as a function of temperature 
and by computing the melting temperature (Tm). Figure 9 shows thermal 
denaturation profile of native HSA, glycated HSA and ROS-glycated HSA. fhe 
melting temperature of native HSA at which 50% of the structural organization is 
lost was found to be 55.2°C. while in case of glycated HSA. it \^as found to be 
74.3°C, a net increase of 19.1°C in the Tm value of glycated HSA was obser\ed 
when compared to its unmodified HSA. Tm value for ROS-glycated HSA was 
found to be 64.0°C showing the net gain of 8.8°C and loss of 10.3°C compared 
with native HSA and glycated HSA, respectively. 
Nati\'e HSA showed typical protein unfolding, evident after 40.0°C. 
however, for both glycated HSA and ROS-glycated HSA, the unfolding of the 
protein started at around 50.0°C, indicating thermal stability on glycation of 
native HSA and its ROS modification, 'fhernial denaturation characteristics of 
native and modified samples are summarized in Table 2. 
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Fig. 9. Thermal denaturation profile of native HSA (-
( ) and ROS-glycaled HSA ( • - ) . 
-), glycated HSA 
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TABLE 2 
UV absorption and thermal denaturation characteristics of native, 
glycated and ROS-glycated HSA 
Parameters Native HSA Glycated HSA ROS-Glycated HSA 
Absorbance 
a t A28()iim 
0.2: 0.13 0.34 
Percent chromicit\ 
at 95 °C 
23.4 
(hypo) 
29.1 
(hyper) 
Melting temperature 
(Tni). °C 
55.0 70 -) 64.0 
Onset of protein 
unfolding on meUint 
("C) 
40.0 50.0 50.0 
50 
Ketoamine estimation of native and modified HSA 
The ketoamine moieties formed by the glycation and ROS modifiealion of 
albumin were measured calorimctrically by using NBT (Fig. 10). 1 he formation 
of ketoamine was found to be 11.2 ± 0.6 and 8.3 ± 0.4 moles/mole of HSA for 
glycated and ROS-g!ycated HSA. respectively. The control non-gl}cated HSA 
gave a negligible ketoamine concentration of 0.3 ± 0.2. 
Protein bound carbonyl groups 
Carbonyl content bound to glycated and ROS-glycated HSA v\as estimated 
by reaction with DNPH. Significant amounts of carbon}'l groups were produced 
on glycation and ROS modification of HSA. The carbon\d contents of glycated 
HSA and ROS-glycated HSA were detected to be 0.31 ± 0.06 and 0.44 ± 0.08 
moles/mole HSA, respectively (Fig. 11). However, the native HSA showed 
negligible amount of protein bound carbonyl group. 0.05 ± .02 moles/mole HSA. 
Determination of number of free amino groups 
The number of free amino groups present in native HSA, glycated HSA and 
ROS-glycated HSA was evaluated (Fig. 12). There is decrease in free amino 
group contents with glycation of HSA. however, after ROS modification on the 
glycated HSA significant increase in the amino group as compared to native and 
glycated HSA. The number of free amino groups in glycated HSA and ROS-
glycated HSA were found to be 7 ± 2 and 29 ± 4 amino groups per mol of HSA. 
respectively. The native HSA showed 16 ± 2 amino groups per mol of HSA. 
Quenching studies 
To examine the glycation of HSA and its oxidafion by ROS has been 
affected b)' scavengers, metal chelators, and non-enzymatic and enzymatic 
antioxidants. Mannitol and sodium azidc are scavengers of OH and O2 '". 
respectively. Metal chelators (DFTAPAC, EDTA), non-enzymatic antioxidant 
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Fig. 10. Level of ketoamines in native HSA, glycated HSA and ROS-glycated 
HSA. 
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Fig. 11. HSA bound carbonyl groups in native HSA, glycated HSA and ROS-
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Fig. 12. Number of free amino groups exposed to the solvent system in native 
HSA, glycated HSA and ROS-glycated HSA. 
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Cu. 
(ascorbic acid), cnzynuitic antioxidants (SOD and catalase) and ollTe'fmhibitor of 
glycation like aminoguanidinc were also used. 
AminogLianidine caused maximum (~ 80%) inhibition of glycation (Fig. 
13). Mannitol exhibited 34% inhibition. Ascorbic acid and sodium azide ga^•c 
30%) and 25%) inhibition, respectively, b^nzymatic antioxidant SOD and catalase 
exhibited small decrease in glycation of HSA (25%) and 10%o inhibition). Metal 
chelators DETAPAC and EDTA showed remarkable inhibition (65%o and 55%o. 
respectively) in glycation of HSA. 
As shown in Figure 14, combination of enzymatic antioxidant SOD and 
catalase exhibited maximum (~ 70%o) inhibition of modification by reaeti\-e 
oxygen species, whereas, both SOD and catalase saparetly showed 40%) and 52%) 
inhibition. Mannitol exhibited significant (65%o) inhibition. Ascorbic acid and 
sodium azide showed 40%) and 25% inhibition, respectively, due to reactive 
oxygen species. Metal chelators DETAPAC and EDTA also showed significant 
inhibition in free radical modification (55%o and 50%), respectively). 
Immunogenicity of native and modified HSA 
The hiimunogenicity of native and modified HSA was determined by 
inducing antibodies in rabbits against native HSA, glycated HSA and ROS-
glycated HSA. The antigenic specificity of induced antibodies were assayed b> 
direct binding and comptetion EITSA. The antigen-antibody bindings were also 
assayed by immunodiffusion. The binding of these antibodies to the immunogens 
was further ascertained by band shift assay. 
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Fig. 13. Effect of free radical scavengers and antioxidants on the modification of 
HSA induced by glucose. The OH scavenger (mannitol 100 niM), O2 ' 
scavanger (sodium azide 100 mM), antioxidant (ascorbic acid 5 mM) 
and metal ions chelators (DETAPAC 100 mM, EDTA lOmM). SOD 
and catalase (500 units/ml) and aminoguanidine (AG) were used at a 
concentration of 5 mM. 
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Fig. 14. Effect of free radical scavenger and antioxidant on the modification of 
glycated HSA induced by ROS. The OH scavengers (mannitol 100 
mM), O: scavanger (100 mM), antioxidant (ascorbic acid 5 mM) and 
metal chelators (DETAPAC 100 mM, EDTA lOmM). SOD and catalase 
were used at 500 Units/ml. 
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Antibodies against native HSA 
1 he antiserum showed a titer of at least 1:12800 when tested by direct 
binding b]LISA (I'ig. 15). Preimmune serum showed negligible binding, hiduccd 
antibodies were found to be specific for the immunogen. Inhibition BLISA 
showed a maximum of 70.4% inhibition (Fig. 16). Fifty percent inhibition was 
achieved with 11.8 |.ig/ml of nati\e USA. The raised antibodies were found to be 
precipitating as observed by immunodiffusion (Fig. 17), showed observable 
precipitating lines between native HSA and native HSA antiserum. 
Purification and binding characterization of native HSA immune 
IgG 
Immunoglobulin G was isolated from pre-immune and immune rabbit 
antiserum of native HSA by affinity chromatography on Protein A-Agarose 
column (Fig. 18). The purity of IgG was evaluated by SDS-polyacrylamide gel 
electrophoresis in absence of a reducing agent. The purified IgG migrated as a 
single band on 7.5% polyacrylamide gel upon electrophoresis (Fig. 18 inset). 
Direct binding ELISA of the purified native HSA IgG showed strong 
reactivity towards immunogen (Fig. 19). Pre-immune IgG from rabbit as negative 
control showed negligible binding. 
Band shift assay 
The binding of native HSA to their immune IgG was further ascertained 
b_\ band shift assay. An increasing in the amount of anti-native HSA IgG 
incubated with constant amount of antigen, for 2 lii- at 37°C and overnight at 4°C, 
caused a propotional increase in the formation of high molecular weight immune 
complexes resulting in increase intensity of the immune complex. However, the 
amount of unbound HSA showed a proportional decrease in its intensity (Fig. 
20). 
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Fig. 15. Direct binding ELISA of native HSA with preimmune (A) and immune 
( • ) sera. Microtitre plates were coated with native HSA 20 fxg/ml). 
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Fig. 16. Inhibition ELISA of anti-native HSA immune (•) and pre-immune (A) 
sera with native HSA. Microtitre plates were coated with native HSA (20 
|a,g/ml) 
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Fig. 17. Outcherlony double immunodiffusion of anti-native HSA antibodies 
with native HSA. Central well contains antigen whereas, well number 
I to 6 contain neat, 1:2, 1:4, 1:8, 1:16 and 1:32 same diluted serum, 
respectively. 
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Fig. 18. Elution profile of anti-native HSA IgG on Protein-A Agarose column. 
Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
62 
I.U 
0.9 
E 0.8 
? 0.7 
< 0.6 -
LU 
O 0.5 
CQ 0.4 
a: 
O 03 
m 
< 0.2 -
0.1 ' 
0.0 1 
/ _ — — — A — — ^ • 
1^ —^ : 1 r 
• — ^ 
1 1 1 1 1 
0 10 20 30 40 50 60 70 
IgG CONCENTRATION, \iglm\ 
80 90 
Fig. 19. Binding of affinity purified anti-native HSA immune IgG (•) and 
preimmune IgG (A) to native HSA. Microtitre plates were coated with 
native HSA (20 fig/ml). 
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Fig. 20. Band shift assay of anti-native HSA IgG binding to native HSA. 
Native HSA (10 |xg) (lane 2) and anti-native HSA IgG (10 ^g) (lane 3) 
were incubated with buffer alone. Increasing amount of immune IgG 
(10, 20, 30 and 40 ^g) with constant amount (10 |jig) of native HSA 
through lanes 4 to 7, respectively were incubated for 2 hr at 37°C and 
overnight at 4 °C. Lane 1 contain protein molecular weight marker 
(98-14 kDa). Electrophoresis was carried out on 5.5% polyacrylamide 
geJ for 3 hr at 50 V. 
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Antibodies against glycated HSA 
Glycated HSA antiserum showed of high titre antibodies (> 1:12800) by 
direct binding ELISA. However, the binding of pre-immune serum was of low-
magnitude (Fig. 21). hi competition ELISA, a maximum of 76% inhibition was 
observed at 20 i^g/ml and 50% inhibition was achieved only at 7.8 jig/ml of 
immunogen (Fig. 22). The antibodies raised against glycated HSA was found to 
be precipitating and also showed fine precipitating line between glycated HSA 
and its antiserum, as observed by immunodiffusion (Fig. 23). 
Purification and binding characterization of glycated HSA 
immune IgG 
Immunoglobulin G was isolated from pre-immune and immune rabbit 
antiserum of glycated HSA by affinity chromatography on Protein A-Agarose 
column (Fig. 24). The purity of IgG was evaluated by SDS-polyacrylamide gel 
electrophoresis in absence of a reducing agent. The purified IgG migrated as a 
single band on 7.5% polyacrylamide gel upon electrophoresis (Fig. 24 inset). 
Direct binding ELISA of the purified glycated HSA IgG showed strong 
reactivity towards its immunogen (Fig. 25). Pre-immune IgG from rabbit as 
negative control showed negligible binding. 
Band shift assay 
The binding of glycated HSA to their immune IgG was further ascertained 
by band shift assay. An increase in the amount of anti-glycated HSA IgG 
incubated with constant amount of antigen, for 2 hr at 37°C and overnight at 4°C, 
caused a proportional increase in the formation of high molecular weight immune 
complexes resulting in increase intensity of the immune complex. However, the 
amount of unbound HSA showed a proportional decrease in its intensity (Fig. 
26). 
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Fig. 2L Direct binding ELISA of glycated HSA with preimmune (A) and 
immune sera (• ) . Microtitre plates were coated with glycated HSA (20 
|ig/ml). 
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Fig. 22. Inhibition ELISA of anli-glycated HSA immune (•) and pre-immune (•) 
sera with glycated HSA. Microtitre plates were coated with glycated HSA 
(20 |.ig/nil) 
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Fig. 23. Outcherlony double immunodiffusion of anti-glycated HSA antibodies 
with glycated HSA. Central well contains antigen whereas, well 
number 1 to 6 contain neat. 1:2, 1:4, 1:8, 1:16 and 1:32 same diluted 
serum. respecti\ cl>. 
68 
1.0 
0.9 
0 1 2 3 4 5 6 7 8 9 10 11 12 
FRACTION NUMBER 
Fig. 24. Elution profile of anti-glycated HSA IgG on Protein-A Agarose 
column. Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide 
gel. 
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Fig. 25. Binding of affinity purified anti-glycated HSA immune IgG (•) and 
preimmune IgG (A) to glycated HSA. Microtitre plates were coated 
with glycated HSA (20 ^ig/ml). 
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Fig. 26. Band shift assay of anli-glycated HSA IgG binding to glycated HSA. 
Glycated HSA (10 ng) (lane 2) and anti-native HSA IgG (10 i^ g) (lane 
3) were incubated with buffer alone. Increasing amount of immune 
IgG (10, 20, 30 and 40 |ig) with constant amount (10 jig) of native 
HSA through lanes 4 to 7, respectively were incubated for 2 hr at 
37°C and overnight at 4°C. Lane 1 contain protein molecular weig ht 
marker (98-14 kDa). Electrophoresis was carried out on 5.5% 
polyacrylamide gel for 3 hr at 50 V. 
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Antibodies against ROS-glycated HSA 
Direct binding ELISA was used to characterize tiie immune response in 
rabbit following immunization with ROS-glycated HSA. ROS-glycalcd HSA was 
highly immunogenic in rabbits. The antiserum showed a titre of at least 1:12800 
when tested by direct binding EIJSA (Fig. 27). Pre-immune serum served as 
negative control, did not show any appreciable binding to ROS-glycated HSA. 
The specificity of anti- ROS-glycated HSA antiserum was evaluated by 
competition ELISA. A maximum of 77.2% inhibition in antibody activity was 
obtained at an immunogen concentration of 20 )ag/ml. The concentration of 
immunogen required for 50% inhibition was 5.8 |ig/ml (Fig. 28). The raised 
antibody was found to be precipitating as observed by immunodiffusion (Fig. 29). 
Purification and binding characterization of ROS-glycated HSA 
immune IgG 
humunoglobulin G was isolated from pre-immune and immune rabbit 
antiserum of ROS-glycated HSA by affinity chromatography on Protein A-
Agarose column (Fig. 30). The purity of IgG was evaluated by SDS-
polyacrylamide gel electrophoresis in absence of a reducing agent. The purified 
IgG migrated as a single band on 7.5% polyacrylamide gel upon electrophoresis 
(Fig. 30 inset). 
Direct binding ELISA of the purified glycated HSA IgG showed strong 
reactivity towards its immunogen (Fig. 31). Pre-immune IgG from rabbit as 
negative control showed negligible binding. 
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Fig. 27. Direct binding ELISA of ROS-glycated HSA with preimmune (A) 
and immune sera (• ) . Microtitre plates were coated with ROS-
glycated HSA (20 ^g/ml). 
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Fig. 28. Inhibition ELISA of anti-ROS-glycated HSA immune (•) and pre-
immune (A) sera witli ROS-glycated HSA. Microtitre plates were 
coated with ROS-glycated HSA (20 ^g/ml). 
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Fig. 29. Outcherlony double immunodiffusion of anti-ROS-glycated HSA 
antibodies with ROS-glycaled HSA. Central well contains antigen 
whereas, well number 1 to 6 contain neat, 1:2. 1:4, 1:8, 1:16 and 1:32 
diluted serum, respectively. 
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Fig. 30. Elution profile of anti-ROS-glycated HSA IgG on Prolein-A Agaros 
column. Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamio 
gel. 
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Binding of affinity purified anti-ROS-glycated HSA immune IgG (•) 
and preimmune IgG (A) to ROS-glycated HSA. Microtitre plates were 
coated with ROS-glycated USA (20 |ig/ml). 
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Band shift assay 
The binding of IU)S-glycatcd USA to their immune IgG was further 
aseertaincd by band shift assa). An increasing amount of anli-ROS-glycatcd USA 
IgG was incubated with constant asnount of antigen, for 2 hr at 37°C and 
oxernight at 4°C. A proportional increase in the formation of high molecular 
weight immune complexes was observed. No increase in the intensity of ICs with 
retarted mobilit)' was evident. Moreover, the amount of unbound HSA showed a 
proportional decrease in its intensity (Fig. 32). 
Immuno-cross reactivity of anti-native HSA antibodies 
The antigenic specificity of the induced anti-native HSA antibodies was 
characterized b\ competitive inhibition assay using various inhibitors like blood 
proteins and nucleic acid (Figs. 33 - 35). A maximum of 78.0% inhibition of anti-
native HSA antibody with immunogen as inhibitor was observed (Fig. 33a). Fifty 
percent inhibition was achiexed with only 9.6 ^g/ml of native FISA. The induced 
antibodies showed a broad spectrum of reaclivit}' as observed bj' its binding to a 
x'ariety of protein antigens. Glycated FISA and ROS-glycaied HSA showed 
inhibitions of 40% and 23%. respectively (Fig. 33a). Native IgG. glycated IgG 
and ROS-glycated IgG showed inhibitions of 9.5%, 31.0%) and 27%o. respectively 
(Fig. 33b). Native BSA, glycated BSA and ROS-glycated BSA showed 37%. 
35% and 33% inhibition, respectively (Fig. 34a). Native poly-L lysine, glycated 
poly-L hsine and ROS-glycated poly-L lysine showed 11.5%), 21%) and 14.1% 
showed inhibition, respectively, at 20 ).ig/ml (Fig. 34b). Twenty weeks glycated 
HSA and ROS-HSA at 20 |_[g/ml showed 28.3% and 31.4% inhibition, 
respccti\eK (Fig. 35a). Fructose modified HSA and native plasmid DNA at 20 
Hg/ml showed 27.1% and 19% inhibition, respectively (Fig. 35b). Table 3 
summarizes the data of the binding characteristics of anti-native HSA IgG as 
determined b\' inhibition liFISA. 
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Fig. 32. Band shift assay of anli-ROS-glycated HSA IgG binding to ROS-
glycated HSA. ROS-glycated HSA (10 ^g) (lane 2) and^anti-ROS-
glycaied HSA IgG (10 ^g) (lane 3) were incubated with buffer alone. 
Increasing amount of immune IgG (10, 20, 30 and 40 |.ig) with 
constant amount (10 f.ig) of ROS-glycated HSA through lanes 4 to 7. 
respectively were incubated for 2 hr at 37°C and overnight at 4°C. 
Lane 1 contain protein molecular weight marker (9-14 kDa). 
Electrophoresis was carried out on 5.5% polyacrvlamide gel for 3 hr 
at 50 V. 
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Fig. 33. Inhibition of anti-nalive HSA IgG binding to native HSA. Microtitre plates 
were coated with native HSA (20 |ig/ml). The competitors were (a) native 
HSA (•), glycated USA (A) and ROS-glycaled HSA (•). (b) natn'c 
human IgG (•), gUcatcd human IgG (A) and ROS-gKcatcd !gG (a). 
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Fig. 34. Inhibition of anli-native HSA IgG binding to native HSA. Microtitre 
plates were coated with native HSA (20 }.ig/ml). The competitors were 
(a) native BSA (•), glycated BSA (A) and ROS-glycatcd BSA (o), (b) 
native poly-L lysine (•), glycated poly-L lysine human (A) and ROS-
glycated poly-L lYsine(»). 
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Fig. 35. Inhibition of anti-native IgG binding to native HSA. Microtitre plates 
were coated with native USA (20 f.ig/ml). The competitors were (a) ROS-
HSA (•). fructated IISA(A), (b) glycated HSA (20 weeks) (•). native 
plasmid DNA(B) . 
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TABLE 3 
Antigenic specificity of anti-native HSA antibodies 
Inhibitors Maximum % inhibition at 20 i^g/ml 
Native HSA 
Glycated HSA 
ROS-glycated HSA 
Native liuman IgG 
Glycated human IgG 
ROS-glycated human IgG 
Native BSA 
Glycated BSA 
ROS-glycated BSA 
Poly-L lysine 
Glycated poly-L lysine 
ROS-ghcatcd poh-L Ksine 
ROS-HSA 
Fructated HSA 
Glycated HSA (20 weeks) 
Plasmid DNA 
78.0 
40.0 
23 0 
95 
31.0 
27.0 
37.0 
35.0 
33 0 
11.5 
21.0 
14.1 
31.4 
27.1 
28.3 
19.0 
ELISA plates were coated with native HSA at 20 |.ig/ml 
Immil no-cross reactivity of anti-glycated HSA antibodies 
The antigenic spcciiicity of the induced anti-glycatcd USA antibodies was 
characteri/cd by competili\e inhibition assay using the immunogen, blood 
proteins, and nucleic acid as inhibitors (Figs. 36-38). A maximum of 88.1% 
inhibition of antibody binding with immunogen as inhibitor was observed (Fig. 
36a). Fifty percent inhibition was achieved with only 6 \.ig/m\ of glycated HS.'\. 
f he induced antibodies showed a broad spectrum of reactivity as observed by its 
binding to a variety of protein antigens. Native HSA and ROS-glycated HSA 
showed inhibitions of 30% and 38%) (Fig. 36a). Nati\'e IgG. gKcated IgG and 
ROS-glycalcd IgG showed inhibitions of 7.6%, 56% and 22.1%, respectively 
(Fig. 36b). Native BSA, glycated BSA and ROS-glycated BSA showed 21.8%. 
50.2%o and 39.1%) inhibition, respectively (Fig. 37a). Native poly-L lysine. 
glycated poly-L lysine and ROS-glycated poly-L lysine showed 17.1%o. 43%o and 
31%o inhibition, respectively, at 20 jig/ml (Fig. 37b). Twenty weeks glycated 
HSA showed a significant inhibition and fifty percent inhibition was achie\'ed 
with 10.8 pg/ml of twenty weeks glycated HSA (Fig. 38a). ROS-HSA at 20 
|.ig/ml showed 29.2%o inhibition (Fig. 38a). Fructose modified HSA and native 
plasmid DNA at 20 |ag/ml showed 52.1%o and 23%o inhibition, respectively (Fig. 
38b). The inhibition data of anti-glycated HSA antibodies with various inhibitors 
are sumnrarized in Table 4. 
Immuno-cross reactivity of anti-ROS-glycated HSA antibodies 
Figures 39 to 41 showed inhibition studies of anti-ROS-glycated HSA 
antibodies with various inhibitors. A maximum of 90.1% inhibition in the binding 
of antibodies with immunogen as inhibitor was observed, concentration of 
immunogen required for fifty percent inhibition was only 8.3 pg/ml (Fig. 39a). 
Native HSA and glycated HSA showed 28.9%o and 31.3% inhibition at 20 (.ig/ml. 
respecti\ely, (Fig. 39a). Native IgG and glycated IgG showed less inhibition of 
19.3%) and 16.5%. respectively (ing. 39b). 
84 
o 
CD 
X 
2 
Z 
LU 
O 
Q: 
LU 
u 
-
20 -
4 0 -
60 -
80 -
1 n n 1 U U 
0 -
-
20 -
4 0 -
60 -
8 0 ^ 
1 0 0 -
'^~~———__ 
t ^ ^ ^ - _ - - ^ 
" ' '~———-_ 
~^~~~~—^'~~~~~~~^  
• I I I ! ) 1 1 
"~~ —•-~tr~—^_ 
1 . 1 1 11 1 1 
~~~~ ' ~^-~-——_ 
^^~~~~~~~-^^ ^ 5 
^^^\ 
1 1 • 1 1 1 1 1 
m 
1 ' 
~ '~~~~ V 
• 
^ ~^~~~A. 
- \ 
• 
' • 1 
— m - — 
• 
• ' r 
a 
1 ] 
v 
b 
—• 
- -
V 
0 . 0 1 0.1 1 10 1 0 0 
I N H I B I T O R C O N C E N T R A T I O N , | j g / m I 
Fi«r. 36. Inhibition of anli-glycated IgG binding to glycated HSA. Microtitre plates 
were coated with glycated HSA (20.0 p-g/ml). The competitors were (a) 
native HSA (o), glycated-HSA (T) and ROS-glycated HSA (a), (b) native 
human IgG (•). glycated human IgG (A) and ROS-gly IgG (•). 
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Fig. 37. Inhibition of anli-glycated HSA IgG binding to glycated HSA. Microtitre 
plates were coated with glycated HSA (20 fig/ml). The competitors were 
(a) native BSA (•), glycated BSA (T) and ROS-glycated BSA (A), (b) 
nati\e poly-L lysine (•), glycated poly-L lysine (A.) and ROS-glycated 
poh-L lysine ( • ) . 
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Fig. 38. Inhibition of anti-glycated USA IgG binding to glycated HSA. Microtilre 
plates were coated with glycated HSA (20.0 [ig/ml). The competitors were 
(a) glycated HSA (20 weeks) (•) , fructated HSA (T) and (b) ROS-HSA 
(a), native plasmid DNA (A), 
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T A B L E 4 
Ant igen ic specif ic ity o f a n t i - g l y c a t e d H S A ant ibod ie s 
Inhibitors Maximum % inhibition at 20 ng/ml 
Native HSA 30.0 
Glycated HSA 88.1 
ROS-glycaled HSA 38.0 
Native liuman IgG 7.6 
Glycated human IgCj 56.0 
ROS-gh'cated human IgC} 22.1 
Native BSA 21.8 
Glycated BSA 50.2 
ROS-glycated BSA 39.1 
Poly-LKsinc 17.1 
Glycated poK-L hsine 43.0 
ROS-gh cated poly-L lysine 31.0 
Glycated HSA (20 weeks) 58.6 
FructatedHSA 52.1 
ROS-HSA 29.2 
Native plasmid DNA 23.0 
RLISA plates were coated v\ith gl\cated HSA at 20 jig/ml 
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Fig. 39. Inhibition of anti-ROS-glycated IgG binding to ROS-giycated HSA. 
Microtitre plates were coated with ROS-giycated HSA (20.0 |ig/ml). 
The competitors were (a) native HSA (T) , glycated-HSA (a) and ROS-
giycated HSA (•), (b) native human IgG (A), glycated human IgG (•) 
and ROS-glycatcd IgG (o). 
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In conlrasl, ROS-glycatcd IgCi was a potent inhibitor, showed a maximum 
inhibition of 49.3%. While natisx- BSA and glycated l^SA showed minimum 
inhibition of 14.6% and KxyK). respectively. ROS-gheated BSA showed 
signillcanl inhibition of (55%)) (Mg. 40a). Fifty percent was achieved with 15 
|.ig/ml of ROS-glycated USA. Native poly L lysine, glycated poly L l3'sine and 
ROS-glycatcd poly L lysine showed 11.3%, 25% and 42.8 inhibition. 
respectively, at 20 ug/ml (Fig. 40b). 
Twent)- weeks glycated FISA and ROS-HSA at 20 pg/mi showed 14.6% 
and 35.3%o inhibition, respectively (Fig. 41a). Fructose modiiled HSA and native 
plasmid DNA at 20 pg/ml showed 14.8% and 9%) inhibition, respectively (Fig. 
41b) 
Antibodies in diabetic patients' sera against native and modified 
HSA 
Sera from diabetic patients were tested for binding to nati\'e and modified 
HSA (glycated HSA and ROS-glycated HSA) by direct binding and competitive 
assay. The stud}' comprised 24 sera from patients suffering from uncontrolled 
hyperglycemia (both types of diabetes mellitus) for long duration, fhc sera from 
nine diabetic patients ha\'ing secondary complications like retinopathy, 
nephropathy and diabetic arteriosclerosis have also been studied. Sera from 
normal or healthy individuals served as controls. Diabetic sera were obtained 
after careful clinical examination of patients which proven positive glucose 
tolerance test attending J. N. Medical College Hospital, A. M. U. Aligarh. 
Diabetic patient's sera showed appreciable binding to glycated HS.A and 
ROS-glycated HSA as compared to native HSA. Similar results were obtained 
with the sera of diabetic patients having secondary complications (Fig. 42). 
fhese patients showed greater recognition to ROS-glycated HSA as compared to 
ulvcated HSA. 
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Fig. 40. Inhibition of anti-ROS-glycated HSA IgG binding to ROS-glycated 
HSA. Microtitre plates were coated with ROS-glycated HSA (20 
l-ig/ml). The competitors were (a) native BSA (T) , gh'cated BSA (•) 
and ROS-glycated BSA (a), (b) native poly-L lysine (•), glycated 
poly-L lysine (o) and ROS-glycated poly-L lysine ( A ) . 
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Fig. 41. Inhibition of anli-ROS-g!ycated HSA IgG binding to ROS-glycated 
HSA. Microtitre plates were coated with ROS-glycated HSA (20.0 
^g/ml). The competitors were (a) glycated HSA (20 weeks) (•) , 
ROS-HSA (a), (b) fructated HSA (•) and native plasmid DNA (•). 
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TABLE 5 
Antigenic specificity of anti-ROS-glycated HSA antibodies 
Inhibitors Maximum % inhibition at 20 {ig/ml 
Native HSA 
Glycated HSA 
ROS-glycated HSA 
Native human IgG 
Glycated human IgG 
ROS-glycated human IgG 
Native BSA 
Glycated BSA 
ROS-glycated BSA 
Poh-L lysine 
Glycated poly-L lysine 
ROS-glycated pol>-L lysine 
Glycated HSA (20 weeks) 
ROS-HSA (20 weeks) 
Fructated HSA 
Native plasmid DNA 
28.0 
31.3 
90.1 
19.3 
16.5 
49.3 
13.0 
16.7 
55.0 
11.3 
25.0 
42.8 
14.6 
J 5 . J 
!4.8 
9.0 
ELISA plates were coated with ROS-glycated HSA at 20 Mg/ml 
Diabetic patients Diabetic Diabetic Diabetic Normai subjects 
(n=24) retinopathy nephropathy artherosclerosis (n=10) 
(n=9) (n=9) (n=9) 
TYPES OF SERA 
Fig. 42. Binding of various diabetic patients' sera to native HSA (D), glycated 
HSA (•) and ROS-glycated HSA (0). Normal human sera served as 
control. The histogram shows the mean absorbance values of the normal 
and the various diabetic patients' sera. 
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However, glycated USA showed greater binding than ROS-glycated HSA 
in sera of diabetic patients having secondary compHcations. Normal human sera 
showed less or negligible binding to native and modified USA. 
Competition I^LISA was carried out to analyze the specific recognition 
of circulating autoantibodies in diabetic patients for native and modified USA. 
The specific binding of the autoantibodies was remarkably higher for modified 
HSA (p < 0.001) than native HSA in all the sera tested. 
Twenty four sera from diabetic patients", the observed maximum 
inhibition with native and glycated HSA was in the range of 16% to 37% and 
32.9% to 59.3%), respectively, (Figs. 43- 48). The inhibition data of native and 
glycated HSA with diabetic patients" sera are summarized in Table 6. 
In the case of diabetic patients having secondary complications, the 
observed inhibition at 20 |ag/ml with native HSA and glycated HSA was in the 
range of be 16% to 33% and 54.1% to 68%, respectively (Figs. 49-51). The 
maximum inhibition (68%)) was found in the patient of diabetic retinopathy (Fig. 
49b). The data of patients" sera having secondary complications exhibited 
significant inhibition (p < 0.001) with glycated HSA as compared to native HSA 
and are summarized in Table 7. 
The specificity of twenty four diabetic patients sera for native and ROS-
glycated HSA was evaluated by inhibition ELISA (Fig. 52- 57). Native HSA 
showed maximum inhibitions ranging from 13% to 33.1%), ROS-glycated FISA 
showed high percent inhibition ranging from 31%) to 62%). The inhibition data of 
native and ROS-glycated HSA with diabetic patients' sera are summarized in 
Table 8. 
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Fig. 43. Detection of autoantibodies against native and gl3'cated HSA in tlie 
diabetic patients' sera, (a) Diabetic patients' sera 1 and 2 by native HSA 
(a, A), and glycated HSA (•, A,), (b) diabetic patients" sera 3 and 4 b\ 
native HSA (u, A) and glycated HSA (•, A). The microtitre plates were 
coated with glycated HSA (20 ^g/ml). 
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Fig. 44. Detection of autoantibodies against native and glycated HSA in tlie 
diabetic patients' sera, (a) Diabetic patients' sera 5 and 6 by native HSA 
(n, A), and glycated USA (•, T), (b) diabetic patients" sera 7 and 8 b\ 
native HSA (D, A) and glycated HSA (•, A). The microtitre plates were 
coated with glycated HSA (20 |-tg/ml). 
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Fig. 45. Detection of autoantibodies against native and glycated HSA in the 
diabetic patients' sera, (a) Diabetic patients' sera 9 and 10 by native 
HSA (n, A), and glycated HSA (•, T) , (b) diabetic patients" sera 11 
and 12 by native HSA (n, A) and glycated HSA (•, T) . The microtitre 
plates were coated with glycated HSA (20 p-g/ml). 
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Fig. 46. Detection of autoantibodies against native and glycated HSA in the 
diabetic patients' sera, (a) Diabetic patients' sera 13 and 14 by native 
HSA (a, A), and glycated HSA (•, • ) , (b) diabetic patients' sera 15 
and 16 by native HSA (n, A) and glycated HSA (•, T) . The microtitre 
plates were coated with glycated HSA (20 i^g/ml). 
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Fig. 47. Detection of autoantibodies against native and glycated HSA in the 
diabetic patients' sera, (a) Diabetic patients' sera 17 and 18 by native 
HSA (n, A), and glycated HSA (•, T), (b) diabetic patients' sera 19 
and 20 by native HSA (•, A) and glycated HSA (•, T). The microtitre 
plates were coated with glycated HSA (20 f.ig/ml). 
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Fig. 48. Detection of autoantibodies against native and glycated HSA in tlie 
diabetic patients' sera, (a) Diabetic patients' sera 21 and 22 by native 
HSA (n, A), and glycated HSA (•, • ) , (b) diabetic patients' sera 23 
and 24 by native HSA (n, A) and glycated HSA (•, T). The microtitre 
plates were coated with glycated HSA (20 |ig/ml). 
TABLE 6 
Antibodies against native HSA and glycated HSA in diabetic 
patients' sera 
Sera No. 
1 
2 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
Mean ± SD 
(%CV) 
Maximum percent 
Native USA 
29.0 
24.0 
23.0 
28.0 
25.0 
30.0 
27.0 
33.0 
16.6 
31.0 
28.0 
26.0 
29.0 
37.0 
24 0 
33.0 
26.6 
27.3 
16.0 
31.7 
21.0 
20.6 
19.0 
22.0 
26.2 ±5.4 
(20.6) 
inhibition at 20 fig/ml 
Ghcaled USA 
56.0 
51.0 
32.9 
54.0 
48.3 
57.0 
43.0 
57.8 
51.0 
57.0 
48.0 
58.0 
59.3 
53.9 
56.4 
53.4 
49.9 
57.3 
45.0 
56.7 
44.7 
41.0 
40.1 
45.6 
50.7 ±7.0 
(13.8) 
ELISA plates were coaled individuaily with native and glycated HSA (20 }ig/ml) 
Significant binding with glycated HSA (p<0.001) than the native HSA in diabetic 
.sera. Values in paranthcsis indicate percent of coefficient of variation. 
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Fig. 49. Detection of autoantibodies against native and glycated HSA in tlie 
normal and diabetic retinopathic patients' sera, (a) Normal and diabetic 
retinopathic patients' sera by native HSA (n, A), and glycated HSA (•. 
T), (b) diabetic retinopathic patients' sera 2 and 3 by native HSA (c, 
A) and glycated HSA (•, T). The microtitre plates were coated with 
glycated HSA (20 ng/ml). 
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Fig. 50. Detection of autoantibodies against native and glycated HSA in tlie 
normal and diabetic ncphropathic patients' sera, (a) Normal and diabetic 
nephropathic patients' sera by native HSA (a, A), and glycated HSA (•. 
T), (b) diabetic nephropathic patients'sera 2 and 3 by native HSA (n, 
A) and glycated HSA {•. T). The microtitre plates were coated with 
glycated HSA (20 ^g/ml). 
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Fig. 51. Detection of autoantibodies against native and glycated HSA in the 
normal and diabetic artherosclerotic patients' sera, (a) Normal and 
diabetic artherosclerotic subjects' sera by native HSA (n, A), and 
glycated HSA (•, T), (b) diabetic artherosclerotic patients' sera 2 and 3 
by native HSA (n, A) and glycated HSA (•, T). The microtitre plates 
were coated with glycated I ISA (20 |.ig/ml). 
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TABLE 7 
Antibodies against native HSA and glycated HSA in diabetic 
patients' sera with secondary complications 
Maximum percent inhibition at 20 ng/ml 
Sera Types Native HSA Glycated HSA 
Diabetic Retinopathy 
1 
2 
^ J 
Diabetic Nephropathy 
1 
2 
Diabetic Artherosclerosis 
1 
2 
"1 
Normal Subjects 
1 
2 
J 
15.3 
16.0 
33.0 
28.2 
17.3 
20.2 
16.7 
14.9 
30.0 
22.0 
13.0 
22.0 
65.2 
68.0 
64.0 
52.1 
62.3 
57.0 
66.2 
63.0 
54.1 
27.0 
19.0 
25.0 
ELISA plates were coated with native and glycated HSA at 20 jig/ml 
Statistically significant binding of glycated HSA (p<0.001) than native HSA in 
diabetic sera. Normal individuals showed negligible binding with either of the 
antigen. 
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Fig. 52. Detection of autoantibodies against native and ROS-glycated HSA in the 
diabetic patients' sera, (a) Diabetic patients' sera 1 and 2 by native HSA 
(n, A), and ROS-glycated HSA (•, A), (b) diabetic patients' sera 3 and 
4 by native HSA (n, A) and glycated HSA (•, A). The microtitre plates 
were coated with ROS-glycated HSA (20 ^ig/ml). 
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Fig. 53. Detection of autoantibodies against native and ROS-glycated HSA in 
tlie diabetic patients" sera, (a) Diabetic patients" sera 5 and 6 by 
native HSA (n, A), and ROS-glycated HSA (•, A), (b) diabetic 
patients" sera 7 and 8 by native HSA (n, A) and glycated HSA (•, A). 
llie microtitrc plates were coated with ROS-glycated HSA (20 
Hg/ml). 
108 
0 . 0 1 0 .1 1 10 1 0 0 
I N H I B I T O R C O N C E N T R A T I O N , | j g / m I 
Fig. 54. Detection of autoantibodies against native and ROS-glycated HSA in 
the diabetic patients" sera, (a) Diabetic patients' sera 9 and 10 by 
native HSA (n, A), and ROS-glycated HSA (•, A), (b) diabetic 
patients' sera U and 12 by native HSA (a, A) and glycated HSA (•, 
A). The microtitre plates were coated with ROS-glycated HSA (20 
).ig/ml). 
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Fig. 55. Detection of autoantibodies against native and ROS-glycated HSA in the 
diabetic patients' sera, (a) Diabetic patients' sera 13 and 14 by native 
HSA (n, A), and ROS-glycated HSA (•, A), (b) diabetic patients' sera 
15 and 16 by native HSA (D, A) and glycated HSA (•, A). The 
microtitre plates were coated with ROS-glycated HSA (20 |xg/ml). 
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Fig. 56. Detection of autoantibodies against native and ROS-glycated HSA in 
tlie diabetic patients' sera, (a) Diabetic patients' sera 17 and 18 by 
native HSA (n, A), and ROS-glycated HSA (•. A), (b) diabetic 
patients' sera 19 and 20 by native HSA (n, A) and glycated HSA (•, 
A). The microlitre plates were coated with ROS-glycated HSA (20 
|ig/ml). 
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Fig. 57. Detection of autoantibodies against native and ROS-glycated HSA in tlie 
diabetic patients' sera, (a) Diabetic patients" sera 21 and 22 by native 
HSA (•, A), and ROS-glycated HSA (•, A), (b) diabetic patients' sera 
23 and 24 by native HSA (n, A) and glycated HSA (•, A). The 
microtitre plates were coated with ROS-glycated HSA (20 jj.g/ml). 
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TABLES 
Antibodies against native HSA and ROS-glycated HSA in 
diabetic patients' sera 
Sera No. 
1 
2 
"1 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
Mean ± SD 
(%CV) 
Maximum percent 
Native HSA 
15.0 
25.0 
27.0 
23.0 
33.1 
26.3 
16.3 
31.0 
32.5 
28.0 
15.0 
23.0 
31.0 
15.3 
29.0 
21.4 
13.0 
25.0 
16.0 
19.0 
15.3 
24.0 
25.2 
14.3 
22.6 i 6.4 
(28,3) 
inhibition at 20 jitj^ /ml 
ROS-Glycaled I fS \ 
31.0 
58.0 
62.0 
59.0 
55.1 
51.3 
60.0 
49,5 
58.6 
50.0 
39.0 
48.5 
60.0 
52.0 
45.0 
61.0 
47.0 
54.0 
38.9 
61.0 
54.0 
51.0 
40.4 
43.0 
51.6±8.5 
(16.5) 
ELISA plates uere coaled with native and ROS-glycated HSA at 20 fxg/mJ 
Significanl binding with ROS-glycatcd USA (p<0.001) than the native HSA in 
diabetic sera. Values in paranlhesis indicate percent of coefilcient ofNariation. 
'^^ 
h^ 
The specific binding of the auloantibodies was remarkably higher for 
ROS-glycated USA (p < 0.001) than nati '^e USA in the sera ol'diabetic patients 
having secondary comphcations (h'igs. 58-60). hi the case of nine sera, the 
observed maximum inhibition with native and ROS-glycated USA was in the 
range of 16% to 37% and 32.9% to 59.3%, respectively. The inhibition data of 
native HSA and ROS-glycated HSA with diabetic patients' sera with secondary 
complications are summarized in Table 9. 
Purification of diabetic patient's IgG 
Diabetic retinopathic patient's IgG (serum 2) purified by affmil\ 
chromatography on Protein A-Agarose column eluted as a s}mmetrical single 
peak (Fig. 61). Purified IgG migrated as a single homogenous band on SDS-
PAGE under non-reducing conditions (Fig. 61, inset). 
Band Shift Assay 
The binding of native and modified HSA to diabetic retinopathic 
patienfs IgG (serum 2) was detected by band shift assay. Constant amount of 
antigens were incubated with var\ing amount of diabetic patient IgG for 2 hr at 
37°C and overnight at 4°C. Immune complexes were eleclrophoresed on 5.5% 
polyaerylamide gel for 3 hr at 50 mV. Figure 62 showed the binding of diabetic 
patient IgG to glycated HSA and Figure 63 showed the binding of diabetic 
patients IgG to ROS-glycated HSA. With increasing concentration of IgG. the 
formation of high molecular weight immune complexes increased as judged by 
increase in intensity of immune complexs, whereas, the amount of unbound HSA 
showed a proportional decrease in its band intensity. 
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Fig. 58. Detection of autoantibodies against native and ROS-glycated HSA in the 
normal and diabetic retinopathic patients' sera, (a) Normal and diabetic 
retinopathic subjects' sera by native HSA (n, A), and ROS-glycated 
HSA (•, T), (b) diabetic retinopathic patients' sera 2 and 3 by native 
HSA (•, A) and glycated HSA (•, T) . The microlitre plates were 
coated with ROS-glycaled I ISA (20 |.ig/ml). 
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Fig. 59. Detection of autoantibodies against native and ROS-glyeated HSA in tlie 
normal and diabetic nephropathic patients' sera, (a) Normal and diabetic 
nephropathic patients' sera by native HSA (n, A), and ROS-glycated 
HSA (•, T), (b) diabetic nephropathic patients' sera 2 and 3 by native 
HSA (n, A) and glycated HSA (•, T) . The microlitre plates were 
coated with ROS-glycatcd USA (20 i-ig/ml). 
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Fig. 60. Detection of autoantibodies against native and ROS-glycated HSA in tlie 
normal and diabetic artherosclerotic patients' sera, (a) Nomial and 
diabetic artherosclerotic subjects' sera by native HSA (D, A), and ROS-
glycated HSA (•, T), (b) diabetic artherosclerotic patients" sera 2 and 3 
by native USA (n, A) and glycated HSA (•, T) . The microtitre plates 
were coated with ROS-glycated HSA (20 |.ig/ml). 
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TABLE 9 
Antibodies against native HSA and ROS-glycated HSA in 
diabetic patients' sera with secondary complications 
Maximum percent inhibition at 20 fig/ml 
Sera Types ^ Native USA ROS-Glycated HSA 
[)iabctic Relinopalhy 
Diabetic Ncphi'opath\ 
Diabetic Artlierosclerosis 
29.0 
30.9 
33.0 
27.0 
16.0 
31.0 
22.0 
14.9 
30.0 
64.3 
59.1 
54.5 
52.4 
50.0 
56.0 
64.0 
53.4 
60.0 
Normal Subjects 
22.0 24.4 
16.4 23.0 
13.0 19.0 
ELISA plates were coated with native and ROS-glycated HSA al 20 jig/ml 
Statistically significant binding of ROS-glycated HSA (p<0.001) than native 
HSA in diabetic sera. Normal individuals showed negligible binding with either 
of the antigen. 
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Fig. 61. Elution profile of diabetic retinopathic patient IgG (serum 2) on 
Protein-A Agarose affinity column. Inset: SDS-PAGE of purified 
IgG on 7.5% poiyacrylamide gel. 
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Fig. 62. liand shift assay of diabetic rctinopathic patient's IgG (serum 2) 
binding to glycated HSA. Glycated HSA (10 [xg) (lane 2) and diabetic 
patient's IgG (10 |ig) (lane 3) were incubated with buffer alone. 
Increasing amounts of patient IgG (10. 20, 30 and 40 }ig) with 
constant amount of glycated HSA (10 jig) through lanes 4 to 7. 
respectively were incubated for 2 hr at 37'C and overnight at 4'C. 
Lane 1 contain protein molecular weight marker (98-14 ki)a). 
lilectrophoresis was carried out on 5.5% polyacrylamide gel for 3 hr 
at 50 V. 
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Fig. 63. Band shift assay of diabetic letinopaUiic patient's IgG (serum 2) binding 
to ROS-g(ycatcd MSA. ROS-glycaled HSA (10 ^g) (lane 2) and diabetic 
patient's IgG (10 |ig) (lane 3) were incubated •with buffer alone. 
Increasing amount of patient IgG (10, 20. 30 and 40 p.g) with constant 
amount of ROS-glycaled HSA (10 [ig) through lanes 4 to 7, respectively 
were incubated for 2 hr at 37"C and overnight at 4°C. Lane 1 contain 
protein molecular weight marker (98-14 kDa). Electrophoresis was 
carried out on 5.5% polyacr>lamide gel for 3 br al 50 V. 
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Probing glycation in diabetic patients using anti-glycated HSA 
antibody 
Albumin and immunoglobu!in-G (IgCj) was isolated from sera of diabetic 
patients showing maximum recognition to both modil'icd USA (diabetic 
retinopathic patients" sera 1-3) (Figs. 64 and 65, respectively). IgCi and albumin 
was also isolated from normal human serum (NHS). The purit\ of IgGs was 
ascertained by a single homogenous band on the 7.5% polyacr\'lamidc gc! (Fig 
64, inset). The purity and concentration of the HSA preparations were ascertained 
by elution profde compared with the commercially available HSA elution profile 
(iMg 65), showing that the isolated protein is indeed serum albumin. 
Anti-glyeated HSA antibod> was used as a probe to deiect effect oi' 
glycation in diabetic patient's serum proteins. Serum albumin isolated from 
normal individuals served as control. Immune complexes were made between 
isolated serum albumin and anti-glycated HSA antibody. Mierotitre plates were 
coated with glycated HSA at the concentration of 20 ug/ml. Isolated serum 
albumin from three diabetic patients showed high recognition to anti-gl\cated 
HSA antibod}, showing inhibition ranging from 51.7% to 62.9% (Fig. 66a). 
Samples of HSA from NFIS showed inhibition of 27% (Fig. 66a). 
Same diabetic patients and normal individual sera have been used to isolate 
IgG. Similarly, the immune complexes were formed between isolated IgGs and 
anti-glycated HSA antibody. The range of inhibition of anti-glyeated HSA 
antibody at 20 j-ig/ml with diabetic patient IgG were found to be 47.4% to 62.9%, 
(Fig. 66b). IgG isolated from NHS gave negligible inhibition of 19% at the same 
concentration (Fig. 66b). 
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Fig. 64. Gel filtration column chromatography of commercially available HSA 
(—A—) and serum isolated albumin (—•—) using Sephacryl^*^ S-
200. Each point represents mean ± SD of four values. 
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Fig. 65. Elution profile of isolated IgG on Protein A-Agarose affinity column. 
Inset: SDS-PAGE of purified IgGs on 7.5% polyacrylamide gel. Each 
point represents mean ± SD of four values. 
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Fig. 66. Inhibition of anti-giycated IgG binding to serum isolated proteins. 
Microtitre plates were coated with glycated HSA (20 jJ-g/ml). The 
competitors were (a) HSA isolated from normal human serum (n) 
and 3 diabetic patients (•, • . A), (b) IgG isolated from normal 
human sera (A) and 3 diabetic patients (•, • , A). 
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Probing ROS damage in diabetic patients using anti-ROS-
glycated HSA antibody 
Serum albumin samples isolated from normal and diabetic patients were 
used. The immune complexes were formed between isolated HSA and anti-ROS-
glycated fiSA antibody. Diabetic patients' isolated albumin samples showed 
inhibition of 45%, 50% and 53%) at 20 |xg/ml (Fig. 67a). However, albumin from 
NHS showed inhibition of only 22%) at 20 jig/ml. 
Isolate IgG from normal and diabetic subjects' was also used to form 
immune complex with anti-ROS-glycated HSA antibody. The range of inhibition 
at 20 |ig/ml with anti-ROS-glycated HSA antibody was 40.3% to 49%, (Fig. 
67b). no appreciable binding was observed with NHS. 
The percent inhibition data of serum isolated proteins from diabetic 
patients' and NHS with anti-glycated and anti-ROS glycated HSA antibody are 
given in Table 10. 
Reactivity of rheumatoid arthritic patients' sera with native and 
modified HSA 
Sera from twelve rheumatoid arthritic patients' both sero negative and 
positive were tested for binding to native, glycated and ROS-glycated HSA. The 
binding pattern of serum antibodies to native and modified HSA samples was 
determined by direct binding ELISA. Nearly all the twelve rheumatoid arthritic 
patients' sera showed stronger binding to glycated HSA (p < 0.001) and ROS-
glycated HSA (p < 0.001) (Fig. 68). No appreciable binding was observed with 
the sera of normal subjects, fhe specificity of arthritic sera for native and both 
modified HSA was evaluated by inhibition ELISA (Fig. 69-71). 
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Fig. 67. Inhibition of anli-ROS-glycated IgG binding to serum isolated 
proteins. Microtitre plates were coated with ROS-glycated HSA (20 
|j.g/ml). The competitors were (a) HSA isolated from one normal 
human serum (A) and 3 diabetic patients' sera (•, • , A), (b) IgG 
isolated from one normal human serum (•) and 3 diabetic patients (•, 
. . A ) . 
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TABLE 10 
Binding of anti-giycated HSA and anti-ROS-glycated HSA 
antibodies to serum isolated proteins from normal and diabetic 
patients' sera 
Serum 
Isolated Proteins 
Maximum percent inhibition at 20 fig/ml 
Glycated HSA ROS-Glycated HSA 
Serum Albumin 
Diabetic Patients 
Normal Subject 
51.7 
47.4 
62.9 
27.0 
45.0 
50.0 
53.2 
22.0 
Human Immunoglobulin G 
Diabetic Patients 
Normal Subject 
45.8 
47.0 
53.0 
19.0 
40.3 
45.0 
49.0 
12.5 
128 
0.80 
0.00 
Rheumatoid arthritic patients Normal subjects (rF4) 
(n=12) 
TYPES OF Sff?A 
Fig. 68. Binding of rheumatoid artiiritic patients' sera to native HSA (D), 
glycated HSA (•) and ROS-glycated HSA (0) . Normal human sera 
serve as control. The histogram shows the mean absorbance \'alues of 
the normal and the rheumatoid arthritic patients" sera. Microtitre 
plates were coated with 20 jxg/ml of respective antigen. 
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Fig. 69. Inhibition of rheumatoid arthritic autoantibodies binding by native. 
glycated and ROS-glycaled HSA. (a) Rheumatoid arthritic sera 1 and 
2 by native 1 ISA (o, D), glycated HSA (• , • ) and ROS-glycated HSA 
(A, T), (b) rheumatoid arthritic sera 3, 4 by native USA (o, D). 
glycated HSA (•, • ) and ROS-glycated HSA (A, • ) . The microtitre 
plates were coated with respective antigens (20 ug/ml). 
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Fig. 70. Inhibition of rheumatoid arthritic autoantibodies binding by native HS A. 
glycated HSA and ROS-glycated HSA. (a) Rheumatoid arthritic sera 5 
and 6 by native HSA (o, D). glycated HSA (•, • ) and ROS-glycated 
HSA (A, T), (b) rheumatoid arthritic sera 7, 8 by native HSA (o, n), 
glycated HSA (•, • ) and ROS-glycated HSA (A, T). The microtitre 
plates were coaled with respective antigens (20 (xg/ml). 
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Fig. 71. Inhibition of rheumatoid arthritic autoantibodies binding by native 
HSA, glycated HSA and ROS-glycated HSA. (a) Rheumatoid arthritic 
sera 9 and 10 by native HSA (o, D), glycated HSA (• , • ) and ROS-
giycated HSA (A, T), (b) rheumatoid arthritic sera 11, 12 by native 
HSA (o. D), glycated HSA (•, • ) and ROS-glycated HSA (A, T). 
The microtitre plates were coated with respective antigen (20 |.ig/ml). 
Native USA showed maximum inhibitions in the range of 13% to 29%. 
however, in twehe rheumatoid arthritic sera, the glycated USA showed high 
percent inhibition ranging from 33% to 55.3%. Similarly ROS-glycatcd USA 
showed still increased percent inhibition ranging from 39'M. to 58.8%. The 
inhibition data of native USA, glycated HSA and ROS-glycated HSA with 
rheumatoid arthritic autoantibodies are summarized in Table 11. 
Purification of rheumatoid arthritic patient IgG 
Rlieumatoid arthritic IgG (serum 11) was purified by affinit} 
chromatography on Protein A-Agarosc column (Fig. 72). SDS-PAGH of purified 
IgG under non-reducing conditions showed a single homogenous band (Fig. 72 
inset). 
Band Shift Assay 
Band shift assa)- was employed to further confirm and visualize the 
interaction of both modified HSA samples with rheumatoid arthritis 
autoantibodies. A constant amount of the antigens was incubated with increasing 
amounts (10-40 |.ig) of rheumatoid arthritis IgG (serum 11) for 2 hr at 37°C and 
overnight at 4°C. These immune complexes were then electrophoresed on 5.5% 
polyacrylamide gel for 3 hr at 50 mV. Figure 73 shows the binding of rheumatoid 
arthritis autoantibodies to glycated USA. Figure 74 shows the binding of 
rheumatoid arthritis autoantibodies to ROS-glycated HSA. With increasing 
concentrations of IgG there is corresponding increase in the formation of high 
molecular weight immune complexes which resulted in observable increase in the 
intensity of immune complex and corresponding decrease in the intensity of 
unbound antigen. 
TABLE U 
Antibodies against native HSA, glycated HSA and ROS-glycated 
HSA^ in rheumatoid arthritic patients^ sera 
Sera No. 
1 
2 
n 
^ 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Mean ± SD 
(%CV) 
M: 
Native USA 
15.0 
28.0 
24.0 
20.0 
29.1 
17.0 
13.0 
17.3 
22.6 
26.0 
18.0 
19.2 
20.7 ±5.2 
(25.1) 
ixitnum percent inhibition 
Glycated HSA 
41.0 
47.0 
46.0 
33.0 
42.9 
51.0 
38.0 
50.0 
52.0 
45.2 
55.3 
48.0 
45.8 ±6.3 
(13.8) 
at 20 ng/ml 
ROS-GlycatedllSA 
53.1 
43.0 
50.0 
45.0 
48.2 
39.0 
58.3 
55.6 
40.6 
54.6 
58.8 
53.0 
49.9 ±6.8 
(13.6) 
ELISA plates were coaled with respective antigens. 
Statistically significant binding with both modified HSA (p<0.001) than native 
HSA. Values in paranthesis indicate percent of coefficient of variation. 
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Fig. 72. Elution profile of rheumatoid arthritic patient's IgG (serum 11) on 
Protein A-Agarose affinity column. Inset: SDS-PAGE of purified IgG 
on 7.5% polyacrylamide gel. 
_o 
Fig. 73. Band shift assay of rheumatoid arthritic patient's IgG (serum 11) 
binding to glycated HSA. Glycated HSA (10 i^g) (lane 2) and 
rheumatoid arthritis patient IgG (10 |ig) (lane 3) were incubated with 
buffer alone. Increasing amounts of patient IgG (10, 20, 30 and 40 jig) 
with constant amount (10 |.ig) of glycated HSA through lanes 4 to 7, 
respectively were incubated for 2 hr at 37°C and overnight at 4'C. 
Lane 1 contain protein molecular weight marker (98-45 kOa). 
Electrophoresis was carried out on 5.5% polyacrylamide gel for 3 hr 
at 50 V. 
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Fig. 74. Band shift assay of rheumatoid arthritic patient's IgG (serum 11) 
binding to ROS-glycated HSA. ROS-glycated HSA (10 ng) (lane 2) 
and rheumatoid arthritic patient IgG (10 ^g) (lane 3) were incubated 
with buffer alone. Increasing amounts of patient IgG (10. 20, 30 and 
40 |.ig) with constant amount (10 i-ig) of ROS-glycated HSA through 
lanes 4 to 7. respectively were incubated for 2 hr at 37°C and 
overnight at 4°C. Lane 1 contains protein molecular weight markers 
(98-45 kDa). l^lectrophoresis was carried out on 5.5% 
polyacrylamide gel for 3 hr at 50 V. 
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(DISCUSSION 
Non-cnzymalyic glycation and oxidation play an important role in the 
pathogenesis of several diseases like diabetes and rheumatoid arthritis (Newkirk 
cl a/., 2003; Jakus, 2003; Schmitt el al., 2005). They also induce the accelerated 
accumulation of AGH products in tissues of diabetic patient, particularly with 
secondary complications like retinopathy, nephropathy and artherosclcrosis 
(Cohen el ciL. 2005; Dclraigne. 2005). Hyperglycemia plays an important role in 
the pathogenesis of diabetic complications by increasing protein glycation with 
the gradual build up of advanced glycation end-products in body tissues. Protein 
glycation and the formation of AGEs are accompanied by increased free radical 
activity, that contributes toward the biomolecular damage in diabetes (Ahmed. 
2005). 
AGE formation is an inevitable process in vivo and can be accelerated under 
pathological conditions such as oxidative stress. Oxidative stress and oxidati\e 
damage to tissues are common end points of chronic diseases such as 
atherosclerosis, diabetes and rheumatoid arthritis. The increase in glyeoxidation 
products in plasma and tissue proteins suggests that oxidative stress is increased 
in diabetes (Baynes and Thorpe. 1999; Ahmed et al.. 2005). In serum and 
synovial fluid of patients with rheumatoid arthritis, high AGE levels, like 
pentosidine have been found (Senolt et al., 2005). hi rheumatoid arthritis the 
generation of AGEs can be increased under oxidative stress (Drinda et al., 2005; 
Sunahori et al.. 2006). The AGE carboxymethyl lysine, was observed to be 
present on macrophages and T cells, suggesting its role in the pathogenesis of 
rheumatoid arthritis (Drinda et al., 2002). 
Preliminary data in the present study indicates an almost exclusive 
formation of glycated HSA on covalent linkage of free amino groups to glucose. 
Glycated HSA was further modified by hydroxyl radicals (OH) , generated b}' 
irradiation of hydrogen peroxide with UV light at 254 nm. The conformational 
perturbation in HSA. generated on modifications, was determined by highh-
sensitive physico-chemical techniques such as polyacrylamide gel 
electrophoresis, spectral analysis, circular dichroism spectropolarimetry, thermal 
denaluration and formation of ketoamine, carbonyl group and free amino group. 
The SDS-polyacrylamidc gel electrophoresis pattern of glycated HSA showed an 
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increase in tiic band intensity as well as broadening of the band towards high and 
low molecular weights, which can be attributed to extensive inter- and 
intramolecular cross-linking due to gl)cation, resulting in the formation of 
aggregates (Bouma el ai, 2003). However, the ROS-glycated USA showed low 
intensity of band perhaps due to the fragmentation of protein into small 
polypeptides by the oxidation with 'OH radicals which cauld not be seen in the 
polyacrylamide gel. 
UV-absorption spectra of glycated HSA showed substantia! 
hypochromicity at \nu\ However, hyperchromicity was obser\cd in ROS-
gl>'cated HSA. lliere was no apparent shift in /.niax for both the modilled HSA. 
GK cation may have caused masking of aromatic amino acids due to aggregation 
of the protein leading to a subsequent decrease in the UV intensity. On the other 
hand, hyperchromicity was observed in ROS-glycated HSA either due to 
unfolding of the aggregates on ROS modification or degradation of polypeptide 
into smaller peptides accompanied by exposure of aromatic amino acids to the 
polar environment. 
Fluorescence spectra of glycated HSA depicted a decrease in the 
fluorescence intensity as compared to the native HSA indicating some 
environmental changes around the chromophobic groups and or masking of these 
groups due to the formation of aggregates causes its shielding (Traverso et ciL. 
1997). Whereas, increased intensity of fluorescence was observed in ROS-
glycated HSA. ROS can degrade the aggregates of the glycated HSA and 
chromophobic groups become more accessible to the polar environment. 
HSA has a unique property in that it contains only one tryptophan residue 
taking this into consideration tryptophan specific fluorescence of native and 
modified HSA was investigated, fhe inhibition in the intensity of tryptophan 
specific fluorescence and its quantum yield after glycation were observed, ROS-
glycated HSA showed increase tryptophan specific fluorescence and its quantum 
)ield. hiterestingly both modified samples showed blue shifts of 20 and 9 mm for 
glycated and ROS-glycated HSA, respectively, indicating that hydrophobic 
groups might be slightly more buried as compared to native HSA. Tryptophan 
specific fluorescence spectra of modified HSA and its quantum yields can be 
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ascribed to the destruction of the residue and/or modification of the tryptophan 
microenvironmcnt (Shaklai el a/.. 1984; Vivan el al., 2001). 
for further analysis of conformational and secondary structural changes 
in native and modified USA, circular dichroism spectropolarimentry was carried 
out. In the spectral region of 200-250 nm, the CD signals of proteins are obtained 
mainly due to the secondary structure (Hennessay el al., 1981; Manavalan, 1983). 
Both the modified samples showed decrease in a-heiix and increase in the/y-sheet 
structure as compared to native their forms. Random coils and turns in the 
secondary structure were also found to increase in the glycated and ROS-glycated 
HSA. Thus, glycation may serve as means for conversion of a -helix to /j'-sheet 
structure in HSA, indicating that glycation results in structural transition from the 
folded soluble form to /i-fibrils in serum albumin (Gomes el al., 2005). 
Differences in the ellipticily within the spectral region of 250-300 nm reflects 
modifications in the immediate structural and electronic environments of the 
aromatic amino acid residues (Creighton, 1991). Moreover, the mean residual 
ellipticity of both modified HSA samples showed slight decrease at 260 nm, 
indicating the presence of less ordered tertiary structures as compared to native. 
As described earlier, sugar reacts with proteins to form stable crosslinks of 
protein giving stable end products (Yim el al., 2001). The thermal denaturation 
profile of glycated HSA and ROS-glycated HSA showed a net increase of 18.1°C 
and 8.8°C, respectively, in the "1 m value as compared to unmodified form. This 
can be attributed to the fact that HSA has multiple positively charged amino 
groups which interact covalently with the negative charges of sugar residues 
exhibiting inter- and intramolecular crosslinking of polypeptides, thereby, 
enhancing conformational stability of modified HSA. However, interaction of 
glycated HSA with the 'OH radicals may caused the disruption of weak bonds 
(hydrogen bonds) or fragmentation of the protein leading to a decrease in the Tm 
\alue compared to its glycated form (Coussons el al., 1997). 
The reaction with NBT is a standard method for the detection of formed 
ketoamines, which allowed to characterize the binding of glucose to the primary 
amino groups on the HSA molecules (Ahmed el al., 2002). It was found that the 
ketoamine generation in glycated HSA was significantly higher than its native 
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form. ROS-glycaled HSA showed slightly lower levels ofkcloamine as eompared 
to gh'catcd form of HSA. Ketoamincs arc early non-en/,ymatic glycalion adducls 
and are important precursors of AC}Ms and hjdroxyl radicals which can disrupt 
the sugar-protein binding resulting in decrease of ketoamine level on ROS 
modification (Ahmed et al., 2002). 
Ketoamines were converted to protein bound carbon\l compounds via a 
protein enediol reaction (Baynes, 1991). The generation of carbonyl groups serve 
as a marker of protein glycoxidation (Bayens and Thorpe. 1999). Modified HSA 
exhibited significant amounts of carbonyl groups, whereas, unmodified HSA 
showed negligible amounts. Moreover. ROS glycated HSA contained the highest 
level of carbonyl groups bound to protein. 
Number of free amino groups of proteins irreversibl) modified due to non-
enzymatic glycation (Travcrso et o/.. 1997). The observed number of free amino 
groups in the glycated HSA reduced to half the in number present in its native 
form, whereas. ROS-glycated HSA showed noteworthy high number of free 
amino groups per molecule of HSA as compared to native HSA. The increased 
number of free amino groups in ROS-glycated HSA may be attributed to the 'OH 
radical modification which lead to the generation of new amino groups by 
polypeptide fragmentation (Baynes and Thorpe, 1999). 
Incubation of modified HSA samples with metal chelators, free radical 
scavengers and antioxidants showed inhibition in the glucose and ROS 
modification (Giardino el al., 1998). Metal chelators can sequester the metal ions 
and hence given respectable inhibition in the glycation (Thornalley et ai. 1999). 
Superoxide and hydroxyl radical are generated during glycation via Fenton 
reaction (Hunt et ai, 1988). Non-enzymatic antioxidants sodium azide, mannitol, 
ascorbic acid and enzymatic antioxidant SOD and catalase showed inhibition in 
glucose modification The addition of non-enzymatic and enzymatic antioxidants 
prevented AGE-induced damage, suggesting an enhanced formation of reactive 
oxygen species. Aminoguanidine is a potent inhibitor of glycation and exhibited 
maximum inhibition in glucose modification (Singh et al., 2001). 
Almost similar results were obtained with metal chelators and showed 
considerable inhibition in ROS modification. Mannitol is a specific quencher of 
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"OH. induced remarkable inhibition in modification. Whereas, sodium azide 
showed least inhibition. Ascorbic acid and SOD exhibited similar inhibitions. 
i'otent inhibition was observed by ceUalase and combination ofcatalase and SOD 
indicating the generation ol' hydrogen peroxide and some amount of superoxide 
during modification. The abo\e results revealed that in ROS modification, 
maximum formation of 'Oil radical occur, however, less amounts of 'O2 were 
generated. These results also showed the formation/presence ofH^Oi (Yim el ui. 
2001). 
Antibodies against native and modified HSA were induced in rabbits b) 
immunization with native, glycated and ROS-giyeatcd HSA which were 
subsequently evaluated by direct binding, immunodiffusion and inhibition assay. 
Both modified HSA showed higher antibody titer than the native form. The 
antigenic specificity of purified IgG of native and modified HSA was ascertained 
by competition and band shift assay. The results revealed a high affinit}' of native 
and modified IgG for their immunogen, suggesting that the induced antibodies 
are immunogen specific and probably recognizing the modified structure or 
conformation of modified HSA samples. 
From the observed data, the modified HSA was found to be more 
immunogenic than its native form in the experimental animals. This could be 
attributed to the feature of hyperglycemia and inflammatory disease rheumatoid 
arthritis wherein, glucose and ROS modification play an major role in the 
production of autoantibodies, thus generating new potential epitopes against 
which the antibodies were raised. Autoantibody targeted against intracellular are 
proteins serological hallmarks of the diabetes mellitus and rheumatoid arthritis 
(Mikino e( al, 1995; Sunahori el al., 2006). AnUglycated HSA antibodies are 
significantly high in the diabetics than in control subjects (Schalkwijk el ai, 
1999), moreover, AGE damaged IgG can be detected in patients with rheumatoid 
arthritis (Pullerits el ai, 2005). 
Glycated forms of IgG, BS.A, poly-L lysine, HSA (20 weeks) and 
fructated HSA showed significant inhibition in the range of 43% to 58.6% with 
anli-glycated HSA antibodies, fhese results demonstrated the preferenfial 
recognition of glucose modified protein by anti-glycated antibody, providing 
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convincing evidence for ihe Ibrmalion ol' common epitopes on protein glycation. 
Anti-ROS-glycalcd USA antibodies showed remarkable inhibition (38.9%-55%) 
with the ROS modified glycated protein inhibitors (ROS-glycated IgG, ROS-
glycaled BSA. ROS-glycated poly-L lysine) and ROS-HSA which suggests an 
appreciable binding of ROS modified proteins to the anli-ROS glycated HSA 
antibodies responsible for the generation of common epitopes on ROS 
modification. However, native forms of all above mentioned protein inhibitors 
did not show significant binding towards anfi-modified HSA antibodies. Native 
plasmid DNA did not show reacti\'ity with either of the antigen. From the data, it 
was predicted that new epitopes have been developed during glycation and 
subsequent ROS modification. From the cross reactixity experiments it was 
concluded that modified HSA antibodies are polyspecifie and cross reacting with 
variety of inhibitors recognizing comman antigenic determinants or altered 
protein conformation. 
AGEs tend to accumulate in the tissues of diabetic patients (Kunie et a I.. 
2005). Protein containing AGEs are highly immunogenic and are recognized b\ 
anU-AGE anfibodies (Reddy el ul, 1995; Ikeda et ai. 1996). Immunoglobulin G 
reactivity towards AGE-HSA was significantly higher in diabetic than in control 
sera (Vay et ai, 2000). Increased production of free radicals by mitochondria 
induced by hyperglycaemia may be responsible for the observed metabolic 
disturbances (Defraigne, 2005). 
In the present study the possible role of native and modified HSA in 
diabetes was investigated. Twenty four sera of diabetic patients, showing high 
titre with glycated HSA and ROS-glycated HSA, were collected for the study. 
These sera showed higher titer with modified HSA than with native polymer as 
ascertained by competition ELISA. The inhibition observed in the order of ROS-
glycated HSA > glycated HSA > native HSA. These results indicate that the 
modified HSA is an effective inhibitor, showing substantial difference in the 
recognition than in its native form. Band shift assay further sustained the binding 
of glycated and ROS-glycated HSA with IgG of diabetic patients. Fhe strong 
binding of diabetic patients' sera IgG towards modified HSA demonstrates the 
possible role of modified 1 ISA in diabetic pathogenesis. 
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Role of native and modilled USA was also probed in the pathogenesis of 
diabetic patients ha\ing secondan compHcations (retinopathy, nephropathy and 
arthcrosclerosis). I'^arlicr studies ha\e shown that diabetic patients with secondary 
comphcations indicate the presence ol' the autoantibodies in the plasma against 
AGl:s (Rahbar and h'igarola, 2(J(J3). Further more, the autoantibodies against 
ACiRs were higher in the patients with the renal failure than in normal subjects or 
diabetic subjects without renal failure (Shibayama el al. 1999). Diabetic 
individuals may exhibit elevated le\els of iron and free copper ions (Cutler, 1978: 
Mateo el uL, 1978), which in the presence of glycated proteins have been shown 
to generate free radicals (Hunt, 1994). These highly reacti\'c species ma) cause 
oxidative degradation of serum proteins and this effect has been used as a 
potential explaination for diabetic secondary complications. In our studies 
maximum recognition of ROS-gl>cated HSA was observed in sera of diabetic 
retinopathic patients followed by the recognition of glycated HSA. Similarly high 
recognition of modified polymers was observed with the sera of nephropathic and 
artherosclerotic diabetic patients. However, no remarkable inhibition was 
observed in normal human sera for both modified antigens. 
I h e level of serum AGl£s could be considered as a marker of later 
de\elopment of secondary complications in both types of diabetes mellitus 
(Defraigne, 2005). Recenth it was found that glucose could probably oxidize to 
form reactive carbonyl compounds, which may react with protein to give 
ghcoxidation products (Valencia el al., 2004). hiimunohistochemical studies 
using anti-AGE antibodies have revealed the presence of AGE modified proteins 
in several tissues under various pathological conditions (Mikino el al., 1995). 
Apart from albumin, the other serum proteins, including immunoglobulins 
and red blood cells are also glycated in diabetic plasma (Myint el al.. 1995). 
Albumin isolated from three diabetic patients recognizes anti-glycated and anti-
ROS-glycated HSA antibodies. IgG isolated from same number of diabetic 
patients recognized anti-glycated and anti-ROS-glycatcd HSA antibodies. 
Whereas, albumin and IgG from normal human sera showed no remarkable 
inhibition. Hence our result is in agreement with the earlier studies that glycated 
serum proteins arc more toxic than their native form (Bouma el al., 2003). 
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The presence of autoantibodies reactive towards native and modified HSA 
m tlie sera of patients with rheumatoid arthritis has also been studied. I'he study 
consisted oi' 12 sera from patients with sero positive and negative. All the sera 
showed higher reacli\ity towards modiiled HSA. hicreased levels of circulating 
autoantibodies have been reported m sera of patients with rheumatoid arthritis 
than the normal subjects (Drinda el ai. 2002). The data presented here clearly 
indicate the presence of circulating antibodies in rheumatoid arthritic sera to 
glycated HSA and ROS-glycated HSA, however, native fISA showed less 
reactivity towards the rheumatoid arthritic sera. It has been well accepted that 
glycation and glycoxidation to protein play a fundamental role in the 
pathogenesis of rheumatoid arthritis (Sunahori et al. 2006). Band shift assa}-
further substantiated the binding of gheated HSA and ROS glycated HSA with 
the circulating antibod}' in rheumatoid arthritic sera. 
The data clearly supports the notion that glucose modified-HSA and 
subsequent ROS attack lead to the generation of circulating autoantibodies in 
rheumatoid arthritic patients. 
Based on the above studies the following conclusions can be drawn: 
1. hieubalion of HSA with glucose resulted in the formation of early and 
advanced glycation end products. 
2. Glycated HSA was further modified by ROS generated by 254 nm 
irradiating in the presence of hydrogen peroxide. 
3. Both the modifications cause major biochemical and biophysical changes 
in HSA. 
4. Native and modified HSA were found immunogenic in experimental 
animals. However, modified HSA are highly immunogenic as compared 
to native HSA. 
> hiduced antibodies of modified HSA were higly specific for the 
immunogens and also showed cross reactivity with glycated and ROS-
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glycated form oi'inhibilor protein.^, showing polyspecificity. 
6. Diabetic autoantibodies recognized the glycated and ROS-glycated USA 
better than the unmodified form. Moreover, the diabetic patients with 
secondary complications showed higher binding to modiiled USA than 
diabetic and normal subjects. 
7. Serum isolated proteins also exhibited significant reacti\'ity towards the 
anti-glycatcd and anti-ROS-ghcated HSA antibodies. 
8. Antibodies in the sera of various rheumatoid arthritic patients were found 
to be more specific for modified antigens than their unmodified analogue. 
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